- IMF Executive Board Concludes 2025 Article IV Consultation with Republic of Korea International Monetary Fund
- Korea Institute Projects 1.9% Growth as Domestic Demand Fuels Economy 조선일보
- The International Monetary Fund (IMF) advised the Lee Jae-myung government, which has set up a “supe.. 매일경제
- Korean economy forecast to grow 1.9 percent next year, but exports will slip 0.5 percent: KIET The Korea Times
- [Monetary Policy Committee Poll] ② Expectations for 2% Growth Next Year Rise… “Bank of Korea Likely to Raise Its Forecast” 아시아경제
Category: 3. Business
-
IMF Executive Board Concludes 2025 Article IV Consultation with Republic of Korea – International Monetary Fund
-
Advanced Micro Devices, Inc. (AMD)
News Highlights:
- Zyphra ZAYA1 becomes the first large-scale Mixture-of-Experts model trained entirely on AMD Instinct™ MI300X GPUs, AMD Pensando™ networking and ROCm open software.
- ZAYA1-base outperforms Llama-3-8B and OLMoE across multiple benchmarks and rivals the performance of Qwen3-4B and Gemma3-12B.
- Memory capacity of AMD Instinct MI300X helped Zyphra simplify its training capabilities, while achieving 10x faster model save times.
SANTA CLARA, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) — AMD (NASDAQ: AMD) announced that Zyphra has achieved a major milestone in large-scale AI model training with the development of ZAYA1, the first large-scale Mixture-of-Experts (MoE) foundation model trained using an AMD GPU and networking platform. Using AMD Instinct™ MI300X GPUs and AMD Pensando™ networking and enabled by the AMD ROCm™ open software stack, the achievement is detailed in a Zyphra technical report published today.
Results from Zyphra show that the model delivers competitive or superior performance to leading open models across reasoning, mathematics, and coding benchmarks—demonstrating the scalability and efficiency of AMD Instinct GPUs for production-scale AI workloads.
“AMD leadership in accelerated computing is empowering innovators like Zyphra to push the boundaries of what’s possible in AI,” said Emad Barsoum, corporate vice president of AI and engineering, Artificial Intelligence Group, AMD. “This milestone showcases the power and flexibility of AMD Instinct GPUs and Pensando networking for training complex, large-scale models.”
“Efficiency has always been a core guiding principle at Zyphra. It shapes how we design model architectures, develop algorithms for training and inference, and choose the hardware with the best price-performance to deliver frontier intelligence to our customers,” said Krithik Puthalath, CEO of Zyphra. “ZAYA1 reflects this philosophy and we are thrilled to be the first company to demonstrate large-scale training on an AMD platform. Our results highlight the power of co-designing model architectures with silicon and systems, and we’re excited to deepen our collaboration with AMD and IBM as we build the next generation of advanced multimodal foundation models.”
Efficient Training at Scale, Powered by AMD Instinct GPUs
The AMD Instinct MI300X GPU’s 192 GB of high-bandwidth memory enabled efficient large-scale training, avoiding costly expert or tensor sharding, which reduced complexity and improving throughput across the full model stack. Zyphra also reported more than 10x faster model save times using AMD optimized distributed I/O, further enhancing training reliability and efficiency. With only a fraction of the active parameters, ZAYA1-Base (8.3B total, 760M active) matches or exceeds the performance of models such as Qwen3-4B (Alibaba), Gemma3-12B (Google), Llama-3-8B (Meta), and OLMoE.1Building on prior collaborative work, Zyphra worked closely with AMD and IBM to design and deploy a large-scale training cluster powered by AMD Instinct™ GPUs with AMD Pensando™ networking interconnect. The jointly engineered AMD and IBM system, announced earlier this quarter, combines AMD Instinct™ MI300X GPUs with IBM Cloud’s high-performance fabric and storage architecture, providing the foundation for ZAYA1’s large-scale pretraining.
For further details on the results, read the Zyphra technical report, the Zyphra blog, and the AMD blog, for comprehensive overviews of the ZAYA1 model architecture, training methodology, and the AMD technologies that enabled its development.
Supporting Resources
About AMD
For more than 50 years AMD has driven innovation in high-performance computing, graphics, and visualization technologies. Billions of people, leading Fortune 500 businesses, and cutting-edge scientific research institutions around the world rely on AMD technology daily to improve how they live, work, and play. AMD employees are focused on building leadership high-performance and adaptive products that push the boundaries of what is possible. For more information about how AMD is enabling today and inspiring tomorrow, visit the AMD (NASDAQ: AMD) website, blog, LinkedIn, and X pages.Contact:
David Szabados
AMD Communications
+1 408-472-2439
david.szabados@amd.comLiz Stine
AMD Investor Relations
+1 720-652-3965
liz.stine@amd.com_________________________
1 Testing by Zyphra as of November 14, 2025, measuring the aggregate throughput of training iterations across the full Zyphra cluster measured in quadrillion floating point operations per second (PFLOPs). The workload was training a model comprised of a set of subsequent MLPs in BFLOAT16 across the full cluster of (128) compute nodes, each containing (8) AMD Instinct™ MI300X GPUs and (8) Pensando™ Pollara 400 Interconnects running a proprietary training stack created by Zyphra. Server manufacturers may vary configurations, yielding different results. Performance may vary based on use of the latest drivers and optimizations. This benchmark was collected with AMD ROCm 6.4.Source: Advanced Micro Devices, Inc.
Released November 24, 2025
Continue Reading
-
Intuit SMB MediaLabs Audiences Now Available on The Trade Desk Platform, Connecting Advertisers With Small and Mid-Market Businesses :: Intuit Inc. (INTU)
Intuit SMB MediaLabs’ latest expansion enables more advertisers to reach small and mid-market businesses with greater precision and relevance
MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–
Intuit Inc., the global financial technology platform that makes TurboTax, Credit Karma, QuickBooks, and Mailchimp, today announced that its SMB MediaLabs audiences are now available on The Trade Desk, providing advertisers with access to Intuit’s first-party small and mid-market business (SMB) audience segments. The partnership facilitates advertisers’ access to Intuit’s SMB MediaLabs, a first-of-its-kind advertising network powered by Intuit’s unmatched first-party business data, through The Trade Desk platform. With this integration, advertisers can seamlessly activate Intuit’s unique small and mid-market business insights to reach SMBs with greater precision and at scale, providing them with highly relevant advertising that connects them with products and services that can help optimize and grow their business. Advertisers will continue to abide by Intuit’s Advertising Guidelines, allowing campaigns to deliver value to Intuit’s SMB customers while adhering to responsible, privacy-conscious standards.Small businesses make up 99% of companies in the U.S.1, making the owners and decision-makers of these businesses a high-value market segment with significant spending power. However, this audience has historically been difficult for advertisers to reach accurately, with campaigns often reliant on fragmented or outdated third-party data, resulting in both wasted ad spend for brands and irrelevant experiences for SMBs. The launch of this integration significantly changes this dynamic, making Intuit’s network of unique audiences, which spans millions of SMBs, more readily accessible to advertisers on The Trade Desk platform. Using aggregated, de-identified insights from the Intuit platform, advertisers can more efficiently connect with verified SMB decision-makers, helping brands improve campaign performance while also delivering more relevant ad experiences for SMBs, to help their businesses grow and thrive.
“This partnership marks a fundamental shift in how B2B marketers will be able to engage small and mid-market businesses. For too long, the industry has struggled with accuracy and relevance in targeting the SMB audience—a critical gap we are now closing,” said Christopher Moneta, Director, SMB MediaLabs, Intuit. “By fusing Intuit’s unique, deterministic SMB insights with the powerful execution capabilities of The Trade Desk, we are setting a new standard. Brands can now confidently deliver highly relevant advertising that reaches the right decision-makers across every channel, while SMBs can more easily discover the products and solutions they need to succeed.”
The Trade Desk is the latest demand-side platform (DSP) to directly partner with the Intuit SMB MediaLabs network, and the first DSP where this first-party SMB data will be discoverable for advertisers, providing them with efficient campaign management capabilities and improved cross-channel measurement. Available through the SMB MediaLabs self-service offerings as an endpoint on the LiveRamp Data Marketplace, the integration also significantly expands the reach of Intuit’s SMB MediaLabs across connected TV, audio, display, and digital out-of-home channels.
“As the first media-buying platform to bring Intuit’s SMB MediaLabs audiences to market discoverably, we’re giving advertisers direct access to one of the most trusted sources of small business intelligence,” said Matthew Fantazier, VP, Data Partnerships, The Trade Desk. “This partnership enables us to help brands connect their messages to real decision-makers, with more precision, transparency, and scale.”
Launched in 2023, Intuit’s SMB MediaLabs allows advertisers to create targeted campaigns that have the potential to reach millions of small and mid-market businesses. Access to this key audience has proven to be game changer for marketers seeking to connect with decision-makers and drive measurable business outcomes.
For more information, visit medialabs.intuit.com and thetradedesk.com.
About Intuit
Intuit is the global financial technology platform that powers prosperity for the people and communities we serve. With approximately 100 million customers worldwide using products such as TurboTax, Credit Karma, QuickBooks, and Mailchimp, we believe that everyone should have the opportunity to prosper. We never stop working to find new, innovative ways to make that possible. Please visit us at Intuit.com and find us on social for the latest information about Intuit and our products and services.
1 According to a report from the U.S. Small Business Administration, published in July 2024.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251124125255/en/
Intuit Media Contact:
Jaymie Sinlao
jaymie_sinlao@intuit.comSource: Intuit Inc.
Released November 24, 2025
Continue Reading
-
Novo Nordisk says Alzheimer's drug trial fails, hammering shares – Reuters
- Novo Nordisk says Alzheimer’s drug trial fails, hammering shares Reuters
- Novo Nordisk shares plunge 9% after Alzheimer’s drug trial fails to hit key target CNBC
- Novo Nordisk’s semaglutide fails to slow Alzheimer’s progression statnews.com
- Can Novo unravel Lilly rally with Alzheimer’s data for GLP-1 Seeking Alpha
- Stock Market Today: Futures Tip Up to Start Week; Novo Nordisk Plummets After Ozempic Alzheimer’s Miss TheStreet
Continue Reading
-
Consumer Spotlight Series: CMA investigates companies for misleading sales practices – Dentons
- Consumer Spotlight Series: CMA investigates companies for misleading sales practices Dentons
- CMA launches major consumer protection drive focused on online pricing practices GOV.UK
- WATCHDOG FINALLY GOES AFTER THE TICKET TITANS — AND ABOUT BLOODY TIME, MUN! theriffreport.co.uk
- Investigations have been opened into eight companies facebook.com
- UK Watchdog probes online pricing practices at StubHub, Viagogo MSN
Continue Reading
-
EMBL: New data initiative accelerates discovery and personalised care for mental health conditions
EMBL-EBI receives UKRI Medical Research Council (MRC) and National Institute for Health and Care Research (NIHR) funding for enhancing and translating mental-health omics data into the Open Targets PlatformSummary
- The Open Psychiatry Project will bring together mental health clinical and omics data across the UK through a newly developed federated data architecture platform.
- Analyses and data summaries will be integrated into the Open Targets Platform to make the results available to the wider scientific and industry community.
- The project has received a £2.3 million investment from UKRI Medical Research Council (MRC) and the National Institute for Health and Care Research (NIHR).
- This project will enable researchers to analyse these sensitive data across secure environments for new insights into mental health conditions and response to existing medications.
Identifying targets for new treatments for mental health conditions could become faster, thanks to a new initiative that, for the first time, will bring patient data together across the UK and translate it to how genes and molecules contribute to mental health symptoms and outcomes.
The Open Psychiatry Project is the first multi-centre initiative to jointly analyse and contrast existing UK mental health research data to derive more powerful insights into these conditions.
Led by Mary-Ellen Lynall at the University of Cambridge, the project team includes Ellen McDonagh as project co-lead from EMBL’s European Bioinformatics Institute (EMBL-EBI) and Open Targets, and other colleagues across multiple UK institutes. People with lived experience of mental health conditions from across the UK co-developed the proposal and will partner with the researchers throughout the project.
The project has received an investment of £2.3 million from the UKRI Medical Research Council (MRC) and the National Institute for Health and Care Research (NIHR).
“The NIHR and the Medical Research Council are leading the way in ensuring advances in data and research lead to improved care for mental health conditions. The Open Psychiatry project will help achieve the government’s ambition for world-class biomedical and health research and innovation,” said Lucy Chappell, Chief Scientific Adviser to the Department of Health and Social Care and Chief Executive of the NIHR. “This data platform will help researchers identify more precise and effective interventions, resulting in faster access to new treatments and better support for patients and their families.”
A unified federated data platform for mental-health clinical and omics data
A significant aim of this project is to establish a data federation analysis system, which will allow researchers to analyse data across multiple secure environments without moving or exposing sensitive health or genetic information, ensuring privacy while enabling powerful new insights.
People with lived experience will co-develop the project website design and content, and help in understanding how scientific knowledge can be tailored to non-specialist users to boost accessibility for patients.
The role of the Open Targets Platform
The project will bring together diverse datasets on how genes, cells, and molecules influence mental health conditions. Most psychiatric conditions have a strong genetic basis; however, responses to current treatments are very diverse and often ineffective. Large-scale data analysis is required to create meaningful insights for patients. A systematic analysis of clinical and omics patient data could transform prediction, diagnosis, and treatment through new and personalised interventions.
The information will be presented on an interactive website, which will offer summaries of patient cohorts. The summary data and key analyses will be integrated into the Open Targets Platform to enhance the existing knowledge on mental-health-related genes, biomarkers, and treatments. This will put the findings into a broader drug discovery context to help translate them into the development of potential new treatments. Overarchingly, this project will help to accelerate scientific discovery, commercial development, and patient involvement in research.
“The Open Psychiatry Project will translate the power of omics data into identifying potential new treatments for mental health conditions,” said Ellen McDonagh, Translational Informatics Director at Open Targets and the EMBL-EBI co-lead for this project. “This is the first major initiative to bring together mental health data for multiple stakeholders in an accessible way, and analysing this information collectively is a key step towards finding new targets for drug development. The findings from this project will be integrated into the Open Targets Platform, where they will enhance existing publicly available data to help identify and prioritise the most promising therapeutic targets.”
One of five funded projects
Receiving investment from the MRC and the NIHR, the Open Psychiatry Project is one of five initiatives that will bring together a fragmented health data landscape.
“UK biomedical and health data is currently fragmented and inaccessible to many, leading to missed opportunities in generating transformative knowledge through research that will accelerate development of life-saving drugs and improve patient care,” said Patrick Chinnery, Executive Chair of the Medical Research Council. “The projects announced today will bring together biomedical and health data in a number of critically important areas, such as mental health and complex surgical conditions in children, and enhance existing services, tools, and standards to create a stimulating research environment that will benefit many.”
More information about this funding and the full press release was originally published on the UKRI website.
Continue Reading
-
Cayenne drives 34,000 kilometres to Icons of Porsche
Proving the durability of Porsche’s first-generation E1 Cayenne, Moussaoui set off with a simple plan: enter Kuwait into his GPS, pack a bag, and hit the road. What followed was an extraordinary four-month journey that showcased the resilience of a showroom-spec Cayenne.
The 22-year-old adventurer covered 28 countries and more than 34,000 km in his stock Cayenne V6 – a car that had already clocked 276,000 km before the trip began. “The whole point of my trip was to do it with a completely stock car,” Moussaoui explained.
Unmodified yet unstoppable: The Cayenne’s true test
Aside from upgrading the headlights with OEM Porsche parts, the Cayenne remained untouched – running on factory 21-inch wheels with low-profile tyres. Despite the risk of potholes, Moussaoui was never stranded.
Speaking at Icons of Porsche in Dubai Design District, Moussaoui shared his motivation: a lifelong passion for Porsche. “Porsche is my forever brand. I wouldn’t have chosen another car for this trip. My parents put me in a 911 (993) when I left the hospital as a newborn – my dad said there was just enough room in the back.”
The only maintenance required for the four-month journey that took him from the UAE deserts to the snow fields of Switzerland was regular oil changes and new spark plugs in London.
“Oil changes are the cheapest insurance to ensure the engine stays strong. It’s the ultimate testament to its durability and it didn’t skip a beat.”
Across deserts and mountains: The route to Icons of Porsche
From Dubai, Mateo drove to Kuwait via Saudi Arabia. From there he continued on to Iraq, Turkey and across to Europe crossing through England, Scotland and Wales.
“The most challenging part of the journey was negotiating the border entry from Kuwait into Iraq around Basra, which was an experience. I spent four hours at the border and there were 20 kiosks for documents and fees.”
After its return to Dubai, Mateo gave it another oil change but it’s still running on the same tyres after giving them a rotation in Monaco at the 13,000 km mark.
Despite conquering Saudi Arabian deserts, jagged mountains of Iraq, snow-capped peaks of Italy, fording lakes in Switzerland and cruising German Autobahns, Mateo decided his E1 Cayenne needed to complete a lap of the legendary Nürburgring Nordschleife.
“It’s insane to think that after completing this massive loop of the world in my Cayenne with over 300,000 km on it, the 20.8 km of the Nürburgring Nordschleife were still the toughest kilometres that car has ever done. But again, it survived without a problem.”
What’s next? Adventures still to come
After some rest for both car and driver, a new expedition is already in the pipeline with Mateo planning to take his Cayenne to visit Jordan, Syria and Lebanon as well as a few more Scandinavian countries and later plans to drive it through Asia, America and Africa.
“I’ve covered 28 countries without a hitch in a car that is absolutely as standard as the day it left the factory, so why would I stop now?”
Continue Reading
-
Disability weights measurement for 148 childhood health statuses in Hunan, China: a study based on face-to-face surveys | Population Health Metrics
Study design
This study utilized PC and PHE methods, which are comparable to those used in GBD 2010 and European surveys measuring adult DWs [17, 18]. However, we differed in our survey approach and survey instruments. We used a paper version of the questionnaire, tailored to the situation, as the survey instrument instead of an electronic questionnaire. Furthermore, we conducted a face-to-face survey instead of an online survey from March 2021 to October 2022.
Research setting and participants
The primary target of the sample for this study was people who had some knowledge or awareness of a particular health state in children. Participants were preferably close contacts of children or children themselves. Due to the face-to-face nature of the survey, the large amount of human, material, and financial resources required, and the limited time available due to the epidemic control during the survey period, the respondents of this study were selected from the parents of children in the birth cohort already established by the research group; the parents of children attending and being hospitalised in Hunan Provincial Children’s Hospital, Xiangya Hospital, Xiangya No. 2 Hospital, Xiangya No. 3 Hospital; and the paediatricians of the community and the general hospitals; The general population living in other urban areas of Hunan Province and the administrative districts of Changsha, as well as university students.
The inclusion criteria for the respondents were: (1) be 18 years of age or older; (2) possess normal intelligence, a certain level of literacy, and the ability to comprehend the questionnaire; and (3) have an understanding of the content and purpose of the study, agree to participate, and voluntarily sign an informed consent form. Exclusion criteria include: (1) participants who did not meet the inclusion criteria; (2) incomplete questionnaire responses; and (3) participants who refused to cooperate or did not sign the informed consent form.
The sample size was estimated in consultation with experts in the field of statistics and computer simulations revealed that pairwise comparisons, with more than five comparisons using Probit regression analysis, were able to identify differences, and we also referred to the published literature [19], where 206 illnesses and injuries were included in face-to-face surveys of 5,750 people. The number of disease and injury categories investigated in our study was 148. The number of pairs for two-by-two comparison is 148*147/2 = 10,878, each questionnaire in this study incorporates 16 PC method pairs, a total of 10,878/16 = 680 different questionnaires are needed for one round of survey, each questionnaire needs to be completed by one person independently, 8 rounds of survey are planned in this study, the sample size to be surveyed is 8*680 = 5440, the PC method of our study investigates a total of 5455 respondents in 8 rounds of survey.
Since it was difficult for us to access high schools or middle schools to survey children under the age of 18 in person. Therefore, we surveyed a random sample of students in colleges and universities to make it more representative of the health preferences of this age group. Our survey involved health state descriptions and the anchoring tool, the PHE method, was more difficult to understand, requiring respondents to have some knowledge and equivalent measures of a certain health state, so we surveyed almost exclusively children’s parents in hospitals and neighbourhoods and required parents to have a certain level of cognition, resulting in an overall high level of education in the included population.
Determination of health statuses
After reviewing relevant literature, we identified 148 childhood health statuses based on the disease spectrum of Chinese children’s outpatient and inpatient services, the Global Burden of Childhood Diseases list, the WHO Children’s Disease Statistical List, and major childhood health statuses gained through interviews with children’s parents, as well as the disease spectrum of pediatric outpatient and inpatient services at comprehensive tertiary hospitals and children’s specialty hospitals (See Supplementary documents 1). The text describes six categories of children’s health statuses: birth defects and congenital disability diseases (24), acute infectious disease (31), chronic diseases and injuries (34), accidental injuries (36), mental and behavioral disorders diseases (14), and malignant neoplasm diseases (9). (See Supplement Table S1).
Table 1 Background characteristics of respondents Lay description of health statuses
The principles for describing children’s health statuses are to use concise, non-clinical vocabulary, to highlight the main functional consequences and symptoms associated with the health statuses, and to keep the description to 50 words or less. The same health statuses assessed in adult DWs were identified by referring to lay descriptions of adult health statuses and incorporating them for children [20,21,22]. In the first phase of lay disease descriptions, we measured the functional and symptomatic dimensions of the 148 childhood health statuses included, using the “International Classification of Functioning, Disability, and Health, (ICF)” (https://apps.who.int/iris/bitstream/handle/10665/42407/9241545429.pdf?sequence=1) assessment scale (See Supplement Table S2). This helps to characterise the specific health statuses of these manifestations. Where possible, descriptions were determined based on standard clinical professional classification systems to accurately reflect the severity of a particular condition. The research team extensively discussed and revised the functional health and symptom presentation of the 148 childhood health statuses before finalising a preliminary version. Pediatric experts and doctors from community health service centers were consulted to review and modify the preliminary textual descriptions. This was done to ensure that they accurately reflected the characteristics, common presentations, and duration of associated symptoms involving the sequelae of impaired functioning. Finally, we obtained versions of the textual descriptions of childhood health statuses suitable for use in general population surveys using the PC and PHE methods (See Supplement Table S1).
Table 2 DW (95%UI) for 148 child health States Health status valuation
A comprehensive evaluation of the 148 children’s health statuses was conducted using the PC and PHE methodologies. The PC technique is an ordinal measure that assesses relative differences in individual functioning and health by comparing pairs of children’s health statuses. It also captures the assessor’s preferred choices for these health statuses. The PHE technique is a group health benefit transformation method that requires the assessor to retrospectively assess two hypothetical health items. The first health item is to prevent 1,000 people from developing a disease that leads to rapid death, while the second health item is to prevent 1,500, 2,000, 3,000, 5,000, or 10,000 people (based on randomly selected bids for each question) from developing a disease that is not fatal (i.e., one of the 148 health statuses for children) but would experience the symptoms and durations mentioned in the descriptions. Evaluators are asked to choose which health program they believe produces greater overall population health benefits. The PHE method is utilised for the purpose of evaluating and comparing health statuses affecting entire populations. This is achieved by estimating the propensity for children to experience a loss of welfare due to different health statuses, and subsequently translating this into an equivalent value of welfare loss.
The 148 childhood diseases were first paired two-by-two, for a total of 148*147/2 = 10,878 pairs. We arranged 16 pairs and 3 PHE questions per questionnaire, each questionnaire needed pairs without put back randomly selected from 10,878 pairs and 3 PHE questions without put back randomly selected from 148 childhood diseases until all pairs were included in the questionnaire. Each round of the survey required the completion of 10,878/16 = 680 different questionnaires (See Supplementary documents 2).
Data collection procedures and instruments
In this study, a paper-based questionnaire served as the primary survey instrument. The questionnaire was developed by the research team in consultation with experts and was finalized based on the pre-survey results. The questionnaire mainly consisted of basic socio-demographic information of the respondents (e.g., age, gender, usual address, type of household registration, marital status, education level, annual household income level, type of occupation, presence of children in the household, presence of medical background, etc.), as well as 16 PC questions and 3 PHE questions.
Trained investigators conducted face-to-face interviews. Respondents were informed of the survey’s purpose and questionnaire content and asked to sign an informed consent form. The enumerator supervised respondents while they completed the questionnaire and answered any questions. The questionnaire was completed in full. Respondents did not receive payment for their participation in the survey. The investigator prompted respondents to imagine two children with the disease and to weigh who was healthier between the two. Two investigators worked in pairs to enter the completed questionnaires into a pre-developed computer program.
Statistical analysis
The statistical analyses for this study were conducted using R software (version 4.3.1), Stata MP software (version 17.0), and Microsoft Excel 2021. Probit regression models were used to estimate relative outcomes for childhood health statuses based on pooled PC data. The result reflects the relative differences in severity between childhood health statuses on a quantitative scale, and also shows participants’ choice preferences for each childhood health statuses [23]. The probit regression model was used to determine the selection of the first disease and injure as the healthier state in pairwise comparisons. A response variable of 1 was assigned to this selection, while a value of 0 was assigned to the alternative selection. The probit regression model incorporated indicator variables for each disease and injure, with a value of 1 assigned to the first state in a PC, −1 to the second state in a PC, and 0 to all states other than the pair being considered. Additionally, the interval regression model was used to analyze the pooled group health equivalence data. Finally, a linear regression model was used to anchor the estimates from the probit regression. Logit transformations based on the PHE responses were performed to map to a DW scale of 0 to 1. Finally, 1000 bootstrap iterations were used to calculate 95% uncertainty intervals (UIs) [17, 18].
In addition, we conducted a trend analysis of the DWs of the childhood health statuses included in this study, to validate the logical soundness of the study and the reliability of the DW values. Trend analysis i.e. by plotting a trend line on the DW values of diseases with severity ratings to see if they logically fit the intuition. RSpearman’s correlation coefficient (rs) was used to test for correlations between the DW values obtained for different subgroups and to identify overall differences in DW values measured under different population characteristics. These factors included gender (male and female), age (≥ 35 and < 35 years), education level (bachelor’s degree/above and below), annual household income (high income ≥ 100,000 yuan and low income < 100,000 yuan), type of household registration (urban and rural), presence of a medical background, and physical labor status (manual and non-manual), whether there are children in the family (with child and without child), and whether there is a medical background (with medical background (MB) and without MB). Using the results of the ICF assessment of 148 children’s health statuses (See Supplement Table S3), we investigated the impact of various functional attributes and symptomatic manifestations on children’s DW values.
Continue Reading
-
US senators call for investigation of scam ads on Facebook and Instagram | US news
US senators Josh Hawley and Richard Blumenthal have asked the heads of the Federal Trade Commission (FTC) and the Securities and Exchange Commission (SEC) to investigate revenue from ads on Facebook and Instagram that promote scams and banned goods.
“The FTC and SEC should immediately open investigations and, if the reporting is accurate, pursue vigorous enforcement action where appropriate” to force Meta to disgorge profits, pay penalties and agree to cease running such advertisements, Hawley and Blumenthal wrote in a letter to the federal agencies.
Earlier this month, Reuters reported that internal documents from late 2024 stated that that year – about $16bn – from illicit advertising. One document noted Meta, which owns Facebook and Instagram, earns $3.5bn in revenue from “higher risk” scam ads every six months. Other documents stated that Meta’s anti-fraud rules didn’t appear to apply to many ads that regulators and the company’s own staff believed “violated the spirit” of its rules against scam advertising.
In response to the Reuters report, Meta said it had reduced user reports of scams by 58% over the last 18 months.
The Hawley-Blumenthal letter “makes claims that are exaggerated and wrong”, Meta spokesman Andy Stone said. “We aggressively fight fraud and scams because people on our platforms don’t want this content, legitimate advertisers don’t want it and we don’t want it either.”
Hawley, a Republican, and Blumenthal, a Democrat, expressed skepticism about Meta’s efforts to combat illicit advertising. They pointed to the company’s “ad library”, a publicly accessible database of advertising that appears on Meta’s social-media platforms.
“Even a short review of Meta’s Ad Library at the time of this letter shows clearly identifiable advertisements for illicit gambling, payment scams, crypto scams, AI deepfake sex services, and fake offers of federal benefits,” they wrote.
The senators cited Reuters reporting that Meta itself estimated its platforms were involved in a third of all scams in the US, and went on to note that the FTC estimates Americans lost $158.3bn to scams last year.
“Scams have been allowed to take over Facebook and Instagram as Meta has drastically cut its safety staff, including for FTC mandated reviews, even as it dumps unimaginable sums into its generative AI projects.“
Blumenthal and Hawley expressed particular concern about fake ads purporting to represent the US government or political figures. They cited an example of a bogus ad that claimed Donald Trump was offering $1,000 to recipients of food assistance.
“While Meta has been warned about advertisement deepfakes impersonating politicians, it still continues to run fraudulent clips,” their letter states. “The beneficiaries of these scams are often cybercrime groups based in China, Sri Lanka, Vietnam and the Philippines.”
Continue Reading
-
Collagenase-mediated extracellular matrix targeting for enhanced drug penetration and therapeutic efficacy in nanoscale delivery systems for cancer therapy | Journal of Nanobiotechnology
Sleeboom JJF, van Tienderen GS, Schenke-Layland K, van der Laan LJW, Khalil AA, Verstegen MMA. The extracellular matrix as hallmark of cancer and metastasis: from biomechanics to therapeutic targets. Sci Transl Med. 2024. https://doi.org/10.1126/scitranslmed.adg3840.
Google Scholar
Paolillo M, Schinelli S. Extracellular matrix alterations in metastatic processes. Int J Mol Sci. 2019;20:4947. https://doi.org/10.3390/ijms20194947.
Google Scholar
Glabman RA, Choyke PL, Sato N. Cancer-associated fibroblasts: tumorigenicity and targeting for cancer therapy. Cancers (Basel). 2022;14:3906. https://doi.org/10.3390/cancers14163906.
Google Scholar
Roma-Rodrigues C, Mendes R, Baptista PV, Fernandes AR. Targeting tumor microenvironment for cancer therapy. Int J Mol Sci. 2019;20:840. https://doi.org/10.3390/ijms20040840.
Google Scholar
Kai F, Drain AP, Weaver VM. The extracellular matrix modulates the metastatic journey. Dev Cell. 2019;49:332–46. https://doi.org/10.1016/j.devcel.2019.03.026.
Google Scholar
Yuan Z, Li Y, Zhang S, Wang X, Dou H, Yu X, et al. Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments. Mol Cancer. 2023;22:48. https://doi.org/10.1186/s12943-023-01744-8.
Google Scholar
Xiong J, Xiao R, Zhao J, Zhao Q, Luo M, Li F, et al. Matrix stiffness affects tumor-associated macrophage functional polarization and its potential in tumor therapy. J Transl Med. 2024;22:85. https://doi.org/10.1186/s12967-023-04810-3.
Google Scholar
Deng B, Zhao Z, Kong W, Han C, Shen X, Zhou C. Biological role of matrix stiffness in tumor growth and treatment. J Transl Med. 2022;20:540. https://doi.org/10.1186/s12967-022-03768-y.
Google Scholar
Zeltz C, Primac I, Erusappan P, Alam J, Noel A, Gullberg D. Cancer-associated fibroblasts in desmoplastic tumors: emerging role of integrins. Semin Cancer Biol. 2020;62:166–81. https://doi.org/10.1016/j.semcancer.2019.08.004.
Google Scholar
De Palma M, Biziato D, Petrova TV. Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer. 2017;17:457–74. https://doi.org/10.1038/nrc.2017.51.
Google Scholar
Kugeratski FG, Atkinson SJ, Neilson LJ, Lilla S, Knight JRP, Serneels J, et al. Hypoxic cancer-associated fibroblasts increase NCBP2-AS2/HIAR to promote endothelial sprouting through enhanced VEGF signaling. Sci Signal. 2019;12:eaan8247. https://doi.org/10.1126/scisignal.aan8247.
Google Scholar
Dzobo K, Dandara C. The extracellular matrix: its composition, function, remodeling, and role in tumorigenesis. Biomimetics. 2023;8:146. https://doi.org/10.3390/biomimetics8020146.
Google Scholar
Theocharis AD, Skandalis SS, Gialeli C, Karamanos NK. Extracellular matrix structure. Adv Drug Deliv Rev. 2016;97:4–27. https://doi.org/10.1016/j.addr.2015.11.001.
Google Scholar
He X, Yang Y, Li L, Zhang P, Guo H, Liu N, et al. Engineering extracellular matrix to improve drug delivery for cancer therapy. Drug Discov Today. 2020;25:1727–34. https://doi.org/10.1016/j.drudis.2020.06.029.
Google Scholar
Gouarderes S, Mingotaud A-F, Vicendo P, Gibot L. Vascular and extracellular matrix remodeling by physical approaches to improve drug delivery at the tumor site. Expert Opin Drug Deliv. 2020;17:1703–26. https://doi.org/10.1080/17425247.2020.1814735.
Google Scholar
Morin PJ. Drug resistance and the microenvironment: nature and nurture. Drug Resist Updat. 2003;6:169–72. https://doi.org/10.1016/S1368-7646(03)00059-1.
Google Scholar
Stylianopoulos T, Munn LL, Jain RK. Reengineering the physical microenvironment of tumors to improve drug delivery and efficacy: from mathematical modeling to bench to bedside. Trends Cancer. 2018;4:292–319. https://doi.org/10.1016/j.trecan.2018.02.005.
Google Scholar
Diener B, Carrick L, Berk RS. In vivo studies with collagenase from Pseudomonas aeruginosa. Infect Immun. 1973;7:212–7. https://doi.org/10.1128/iai.7.2.212-217.1973.
Google Scholar
Lammers T. Nanomedicine tumor targeting. Adv Mater. 2024. https://doi.org/10.1002/adma.202312169.
Google Scholar
Hebert JD, Myers SA, Naba A, Abbruzzese G, Lamar JM, Carr SA, et al. Proteomic profiling of the ECM of xenograft breast cancer metastases in different organs reveals distinct metastatic niches. Cancer Res. 2020;80:1475–85. https://doi.org/10.1158/0008-5472.CAN-19-2961.
Google Scholar
Naba A, Clauser KR, Lamar JM, Carr SA, Hynes RO. Extracellular matrix signatures of human mammary carcinoma identify novel metastasis promoters. Elife. 2014;3:e01308. https://doi.org/10.7554/eLife.01308.
Google Scholar
Mai Z, Lin Y, Lin P, Zhao X, Cui L. Modulating extracellular matrix stiffness: a strategic approach to boost cancer immunotherapy. Cell Death Dis. 2024;15:307. https://doi.org/10.1038/s41419-024-06697-4.
Google Scholar
Cheng PSW, Zaccaria M, Biffi G. Functional heterogeneity of fibroblasts in primary tumors and metastases. Trends Cancer. 2025;11:135–53. https://doi.org/10.1016/j.trecan.2024.11.005.
Google Scholar
Barbazán J, Matic Vignjevic D. Cancer associated fibroblasts: is the force the path to the dark side? Curr Opin Cell Biol. 2019;56:71–9. https://doi.org/10.1016/j.ceb.2018.09.002.
Google Scholar
Chen Y, McAndrews KM, Kalluri R. Clinical and therapeutic relevance of cancer-associated fibroblasts. Nat Rev Clin Oncol. 2021;18:792–804. https://doi.org/10.1038/s41571-021-00546-5.
Google Scholar
Margadant C, Sonnenberg A. Integrin–TGF-β crosstalk in fibrosis, cancer and wound healing. EMBO Rep. 2010;11:97–105. https://doi.org/10.1038/embor.2009.276.
Google Scholar
Strating E, Verhagen MP, Wensink E, Dünnebach E, Wijler L, Aranguren I, et al. Co-cultures of colon cancer cells and cancer-associated fibroblasts recapitulate the aggressive features of mesenchymal-like colon cancer. Front Immunol. 2023;14:1053920. https://doi.org/10.3389/fimmu.2023.1053920.
Google Scholar
Yang Y, Sun H, Yu H, Wang L, Gao C, Mei H, et al. Tumor-associated-fibrosis and active collagen-CD44 axis characterize a poor-prognosis subtype of gastric cancer and contribute to tumor immunosuppression. J Transl Med. 2025;23:123. https://doi.org/10.1186/s12967-025-06070-9.
Google Scholar
Bigos KJA, Quiles CG, Lunj S, Smith DJ, Krause M, Troost EGC, et al. Tumour response to hypoxia: understanding the hypoxic tumour microenvironment to improve treatment outcome in solid tumours. Front Oncol. 2024;14:1331355. https://doi.org/10.3389/fonc.2024.1331355.
Google Scholar
Rubinstein-Achiasaf L, Morein D, Ben-Yaakov H, Liubomirski Y, Meshel T, Elbaz E, et al. Persistent inflammatory stimulation drives the conversion of MSCs to inflammatory CAFs that promote pro-metastatic characteristics in breast cancer cells. Cancers (Basel). 2021;13:1472. https://doi.org/10.3390/cancers13061472.
Google Scholar
Cox TR. The matrix in cancer. Nat Rev Cancer. 2021. https://doi.org/10.1038/s41568-020-00329-7.
Google Scholar
Connor A, Gallinger S. Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data. Nat Rev Cancer. 2022;22:131–42. https://doi.org/10.1038/s41568-021-00418-1.
Google Scholar
Zhang J, Miao L, Guo S, Zhang Y, Zhang L, Satterlee A, et al. Synergistic anti-tumor effects of combined gemcitabine and cisplatin nanoparticles in a stroma-rich bladder carcinoma model. J Control Release. 2014;182:90–6. https://doi.org/10.1016/j.jconrel.2014.03.016.
Google Scholar
Cabral H, Matsumoto Y, Mizuno K, Chen Q, Murakami M, Kimura M, et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol. 2011;6:815–23. https://doi.org/10.1038/nnano.2011.166.
Google Scholar
Stylianopoulos T, Jain RK. Combining two strategies to improve perfusion and drug delivery in solid tumors. Proc Natl Acad Sci U S A. 2013;110:18632–7. https://doi.org/10.1073/pnas.1318415110.
Google Scholar
Li Q, Yang C, Li J, Wang R, Min J, Song Y, et al. The type I collagen paradox in PDAC progression: microenvironmental protector turned tumor accomplice. J Transl Med. 2025;23:744. https://doi.org/10.1186/s12967-025-06778-8.
Google Scholar
Masamune A, Kikuta K, Watanabe T, Satoh K, Hirota M, Hamada S, et al. Fibrinogen induces cytokine and collagen production in pancreatic stellate cells. Gut. 2009;58:550–9. https://doi.org/10.1136/gut.2008.154401.
Google Scholar
Bulle A, Lim K-H. Beyond just a tight fortress: contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer. Signal Transduct Target Ther. 2020;5:1–12. https://doi.org/10.1038/s41392-020-00341-1.
Google Scholar
Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA. The pancreas cancer microenvironment. Clin Cancer Res. 2012;18:4266–76. https://doi.org/10.1158/1078-0432.CCR-11-3114.
Google Scholar
Karousou E, D’Angelo ML, Kouvidi K, Vigetti D, Viola M, Nikitovic D, et al. Collagen VI and Hyaluronan: The Common Role in Breast Cancer. Biomed Res Int. 2014;2014:606458. https://doi.org/10.1155/2014/606458.
Google Scholar
Fang M, Yuan J, Peng C, Li Y. Collagen as a double-edged sword in tumor progression. Tumor Biol. 2014;35:2871–82. https://doi.org/10.1007/s13277-013-1511-7.
Google Scholar
Yu S, Zhang C, Xie K-P. Therapeutic resistance of pancreatic cancer: roadmap to its reversal. Biochimica et Biophysica Acta (BBA). 2021;1875:188461. https://doi.org/10.1016/j.bbcan.2020.188461.
Google Scholar
Hosein AN, Brekken RA, Maitra A. Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nat Rev Gastroenterol Hepatol. 2020;17:487–505. https://doi.org/10.1038/s41575-020-0300-1.
Google Scholar
Heydari S, Tajik F, Safaei S, Kamani F, Karami B, Dorafshan S, et al. The association between tumor-stromal collagen features and the clinical outcomes of patients with breast cancer: a systematic review. Breast Cancer Res. 2025;27:69. https://doi.org/10.1186/s13058-025-02017-6.
Google Scholar
Hruska AM, Yang H, Leggett SE, Guo M, Wong IY. Mechanobiology of Collective Cell Migration in 3D Microenvironments. 2023; 1–32. https://doi.org/10.1007/978-3-031-22802-5_1
Henke E, Nandigama R, Ergun S. Extracellular matrix in the tumor microenvironment and its impact on cancer therapy. Front Mol Biosci. 2020;6:160. https://doi.org/10.3389/fmolb.2019.00160.
Google Scholar
Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res. 2000;60:2497–503.
Google Scholar
Sykes EA, Dai Q, Sarsons CD, Chen J, Rocheleau JV, Hwang DM, et al. Tailoring nanoparticle designs to target cancer based on tumor pathophysiology. Proc Natl Acad Sci U S A. 2016;113:E1142-51. https://doi.org/10.1073/pnas.1521265113.
Google Scholar
Pluen A, Boucher Y, Ramanujan S, McKee TD, Gohongi T, di Tomaso E, et al. Role of tumor–host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. Proc Natl Acad Sci U S A. 2001;98:4628–33. https://doi.org/10.1073/pnas.081626898.
Google Scholar
Nichols JW, Bae YH. Odyssey of a cancer nanoparticle: from injection site to site of action. Nano Today. 2012;7:606–18. https://doi.org/10.1016/j.nantod.2012.10.010.
Google Scholar
Ramanujan S, Pluen A, McKee TD, Brown EB, Boucher Y, Jain RK. Diffusion and convection in collagen gels: implications for transport in the tumor interstitium. Biophys J. 2002;83:1650. https://doi.org/10.1016/S0006-3495(02)73933-7.
Google Scholar
Erikson A, Andersen HN, Naess SN, Sikorski P, Davies CdeL. Physical and chemical modifications of collagen gels: impact on diffusion. Biopolymers. 2008;89:135–43. https://doi.org/10.1002/bip.20874.
Google Scholar
Chauhan VP, Lanning RM, Diop-Frimpong B, Mok W, Brown EB, Padera TP, et al. Multiscale measurements distinguish cellular and interstitial hindrances to diffusion in vivo. Biophys J. 2009;97:330–6. https://doi.org/10.1016/j.bpj.2009.03.064.
Google Scholar
He X, Yang Y, Han Y, Cao C, Zhang Z, Li L, et al. Extracellular matrix physical properties govern the diffusion of nanoparticles in tumor microenvironment. Proc Natl Acad Sci U S A. 2023. https://doi.org/10.1073/pnas.2209260120.
Google Scholar
Park JE, Lenter MC, Zimmermann RN, Garin-Chesa P, Old LJ, Rettig WJ. Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts*. J Biol Chem. 1999;274:36505–12. https://doi.org/10.1074/jbc.274.51.36505.
Google Scholar
Santos AM, Jung J, Aziz N, Kissil JL, Puré E. Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J Clin Invest. 2009;119:3613–25. https://doi.org/10.1172/JCI38988.
Google Scholar
Murakami M, Ernsting MJ, Undzys E, Holwell N, Foltz WD, Li S-D. Docetaxel conjugate nanoparticles that target α-smooth muscle actin-expressing stromal cells suppress breast cancer metastasis. Cancer Res. 2013;73:4862–71. https://doi.org/10.1158/0008-5472.CAN-13-0062.
Google Scholar
Teng F, Tian W-Y, Wang Y-M, Zhang Y-F, Guo F, Zhao J, et al. Cancer-associated fibroblasts promote the progression of endometrial cancer via the SDF-1/CXCR4 axis. J Hematol Oncol. 2016;9:8. https://doi.org/10.1186/s13045-015-0231-4.
Google Scholar
Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012;487:500–4. https://doi.org/10.1038/nature11183.
Google Scholar
Duluc C, Moatassim-Billah S, Chalabi-Dchar M, Perraud A, Samain R, Breibach F, et al. Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance. EMBO Mol Med. 2015;7:735–53. https://doi.org/10.15252/emmm.201404346.
Google Scholar
Huang S, Rui F, Jun X, Shenghong Q, Huan Z, Jun D, et al. Evaluation of the tumor targeting of a FAPα-based doxorubicin prodrug. J Drug Target. 2011;19:487–96. https://doi.org/10.3109/1061186X.2010.511225.
Google Scholar
Akinboye ES, Brennen WN, Rosen DM, Bakare O, Denmeade SR. Iterative design of emetine-based prodrug targeting fibroblast activation protein (FAP) and dipeptidyl peptidase IV DPPIV using a tandem enzymatic activation strategy. Prostate. 2016;76:703–14. https://doi.org/10.1002/pros.23162.
Google Scholar
Eikenes L, Bruland ØS, Brekken C, Davies CDL. Collagenase increases the transcapillary pressure gradient and improves the uptake and distribution of monoclonal antibodies in human osteosarcoma xenografts. Cancer Res. 2004;64:4768–73. https://doi.org/10.1158/0008-5472.CAN-03-1472.
Google Scholar
Kato M, Hattori Y, Kubo M, Maitani Y. Collagenase-1 injection improved tumor distribution and gene expression of cationic lipoplex. Int J Pharm. 2012;423:428–34. https://doi.org/10.1016/j.ijpharm.2011.12.015.
Google Scholar
McKee TD, Grandi P, Mok W, Alexandrakis G, Insin N, Zimmer JP, et al. Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic Herpes simplex virus vector. Cancer Res. 2006;66:2509–13. https://doi.org/10.1158/0008-5472.CAN-05-2242.
Google Scholar
Kim M, Hamilton SE, Guddat LW, Overall CM. Plant collagenase: unique collagenolytic activity of cysteine proteases from ginger. Biochimica et Biophysica Acta (BBA). 2007;1770:1627–35. https://doi.org/10.1016/j.bbagen.2007.08.003.
Google Scholar
Raskovic B, Bozovic O, Prodanovic R, Niketic V, Polovic N. Identification, purification and characterization of a novel collagenolytic serine protease from fig (Ficus carica var. Brown Turkey) latex. J Biosci Bioeng. 2014;118:622–7. https://doi.org/10.1016/j.jbiosc.2014.05.020.
Google Scholar
Peptidase M9A/M9B, collagenase, bacterial . [cited 2025 Jul 29]. https://www.ebi.ac.uk/interpro/entry/InterPro/IPR002169/. Accessed 29 Jul 2025
Q9X721 · COLG_HATHI [Internet]. [cited 2025 Jul 29]. https://www.uniprot.org/uniprotkb/Q9X721/entry. Accessed 29 Jul 2025
Collagenase [Internet]. [cited 2025 Jul 29]. https://www.ebi.ac.uk/interpro/entry/pfam/PF01752/. Accessed 29 Jul 2025
Rawlings ND, Barrett AJ, Bateman A. MEROPS: the database of proteolytic enzymes, their substrates and inhibitors. Nucleic Acids Res. 2012;40:D343–50. https://doi.org/10.1093/nar/gkr987.
Google Scholar
Mookhtiar KA, Van Wart HE. Clostridium histolyticum collagenases: a new look at some old enzymes. Matrix. 1992;1(Suppl):116–26.
Google Scholar
Hoy SM. Collagenase Clostridium histolyticum: a review in Peyronie’s disease. Clin Drug Investig. 2020;40:83–92. https://doi.org/10.1007/s40261-019-00867-5.
Google Scholar
Van Wart HE, Steinbrink DR. A continuous spectrophotometric assay for Clostridium histolyticum collagenase. Anal Biochem. 1981;113:356–65. https://doi.org/10.1016/0003-2697(81)90089-0.
Google Scholar
Matsushita O, Koide T, Kobayashi R, Nagata K, Okabe A. Substrate recognition by the collagen-binding domain of Clostridium histolyticum class I collagenase. J Biol Chem. 2001;276:8761–70. https://doi.org/10.1074/jbc.M003450200.
Google Scholar
Matsushita O, Jung C-M, Minami J, Katayama S, Nishi N, Okabe A. A study of the collagen-binding domain of a 116-kDa Clostridium histolyticum collagenase*. J Biol Chem. 1998;273(6):3643–8. https://doi.org/10.1074/jbc.273.6.3643.
Google Scholar
Matsushita O, Jung C-M, Katayama S, Minami J, Takahashi Y, Okabe A. Gene duplication and multiplicity of collagenases in Clostridium histolyticum. J Bacteriol. 1999;181:923–33. https://doi.org/10.1128/jb.181.3.923-933.1999.
Google Scholar
The R-B, Family C. The Collagen Family. Cold Spring Harb Perspect Biol. 2011;3:a004978–a004978. https://doi.org/10.1101/cshperspect.a004978.
Google Scholar
Bella J, Hulmes DJS. Fibrillar Collagens. Fibrous Prot Struct Mech. 2017. https://doi.org/10.1007/978-3-319-49674-0_14.
Google Scholar
Amirrah IN, Lokanathan Y, Zulkiflee I, Wee MFMR, Motta A, Fauzi MB. A comprehensive review on collagen type I development of biomaterials for tissue engineering: from biosynthesis to bioscaffold. Biomedicines. 2022;10:2307. https://doi.org/10.3390/biomedicines10092307.
Google Scholar
Eckhard U, Schönauer E, Nüss D, Brandstetter H. Structure of collagenase G reveals a chew and digest mechanism of bacterial collagenolysis. Nat Struct Mol Biol. 2011;18:1109–14. https://doi.org/10.1038/nsmb.2127.
Google Scholar
Eckhard U, Schönauer E, Brandstetter H. Structural basis for activity regulation and substrate preference of clostridial collagenases G, H, and T. J Biol Chem. 2013;288:20184–94. https://doi.org/10.1074/jbc.M112.448548.
Google Scholar
Syed F, Thomas AN, Singh S, Kolluru V, Emeigh Hart SG, Bayat A. In vitro study of novel collagenase (XIAFLEX®) on Dupuytren’s disease fibroblasts displays unique drug related properties. PLoS One. 2012;7:e31430. https://doi.org/10.1371/journal.pone.0031430.
Google Scholar
Watanabe-Nakayama T, Itami M, Kodera N, Ando T, Konno H. High-speed atomic force microscopy reveals strongly polarized movement of clostridial collagenase along collagen fibrils. Sci Rep. 2016;6:28975. https://doi.org/10.1038/srep28975.
Google Scholar
Mandl I. Bacterial collagenases and their clinical applications. Arzneimittelforschung. 1982;32:1381–4.
Google Scholar
Ramundo J, Gray M. Collagenase for enzymatic debridement: a systematic review. J Wound Ostomy Continence Nurs. 2009;36:S4. https://doi.org/10.1097/WON.0b013e3181bfdf83.
Google Scholar
Drugs@FDA: FDA-Approved Drugs. [cited 2025 Jul 29]. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process. Accessed 29 Jul 2025
Waycaster C, Milne CT. Clinical and economic benefit of enzymatic debridement of pressure ulcers compared to autolytic debridement with a hydrogel dressing. J Med Econ. 2013;16:976–86. https://doi.org/10.3111/13696998.2013.807268.
Google Scholar
Ramundo J, Gray M. Enzymatic wound debridement. J Wound Ostomy Continence Nurs. 2008;35:273. https://doi.org/10.1097/01.WON.0000319125.21854.78.
Google Scholar
Kirshen C, Woo K, Ayello EA, Sibbald RG. Debridement: a vital component of wound bed preparation. Adv Skin Wound Care. 2006;19:518.
Google Scholar
Karagol BS, Okumus N, Dursun A, Karadag N, Zencıroglu A. Early and successful enzymatic debridement via collagenase application to pinna in a preterm neonate. Pediatr Dermatol. 2011;28:600–1. https://doi.org/10.1111/j.1525-1470.2011.01546.x.
Google Scholar
Waycaster C, Carter MJ, Gilligan AM, Mearns ES, Fife CE, Milne CT. Comparative cost and clinical effectiveness of clostridial collagenase ointment for chronic dermal ulcers. J Comp Eff Res. 2018;7:149–65. https://doi.org/10.2217/cer-2017-0066.
Google Scholar
Abdel Raheem A, Johnson M, Ralph D, Garaffa G. Collagenase clostridium histolyticum: a novel medical treatment for Peyronie’s disease. Minerva Urol Nefrol. 2018. https://doi.org/10.23736/S0393-2249.18.03118-1.
Google Scholar
Furtado TP, Osadchiy V, Andino JJ, Eleswarapu SV, Mills JN. Collagenase Clostridium histolyticum for Peyronie’s disease: a contemporary atlas of complications and their management. Sex Med Rev. 2024;12:491–6. https://doi.org/10.1093/sxmrev/qeae004.
Google Scholar
FDA Approves Xiaflex for Debilitating Hand Condition. [cited 2025 Jul 29]. https://www.prnewswire.com/news-releases/fda-approves-xiaflex-for-debilitating-hand-condition-83391072.html. Accessed 29 Jul 2025
Hurst LC, Badalamente MA, Hentz VR, Hotchkiss RN, Kaplan FTD, Meals RA, et al. Injectable collagenase Clostridium histolyticum for Dupuytren’s contracture. N Engl J Med. 2009;361:968–79. https://doi.org/10.1056/NEJMoa0810866.
Google Scholar
Peimer CA, Wilbrand S, Gerber RA, Chapman D, Szczypa PP. Safety and tolerability of collagenase Clostridium histolyticum and fasciectomy for Dupuytren’s contracture. J Hand Surg Eur Vol. 2015;40:141–9. https://doi.org/10.1177/1753193414528843.
Google Scholar
Lunt SJ, Fyles A, Hill RP, Milosevic M. Interstitial fluid pressure in tumors: therapeutic barrier and biomarker of angiogenesis. Future Oncol. 2008;4:793–802. https://doi.org/10.2217/14796694.4.6.793.
Google Scholar
Cairns R, Papandreou I, Denko N. Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Mol Cancer Res. 2006;4:61–70. https://doi.org/10.1158/1541-7786.MCR-06-0002.
Google Scholar
Yata T, Lee ELQ, Suwan K, Syed N, Asavarut P, Hajitou A. Modulation of extracellular matrix in cancer is associated with enhanced tumor cell targeting by bacteriophage vectors. Mol Cancer. 2015;14:110. https://doi.org/10.1186/s12943-015-0383-4.
Google Scholar
Cemazar M, Golzio M, Sersa G, Escoffre J-M, Coer A, Vidic S, et al. Hyaluronidase and collagenase increase the transfection efficiency of gene electrotransfer in various murine tumors. Hum Gene Ther. 2012;23:128–37. https://doi.org/10.1089/hum.2011.073.
Google Scholar
Lo Cicero A, Campora S, Lo Buglio G, Cinà P, Lo Pinto M, Scilabra SD, et al. Enhancing therapeutic efficacy through degradation of endogenous extracellular matrix in primary breast tumor spheroids. FEBS J. 2025. https://doi.org/10.1111/febs.70069.
Google Scholar
Fan D, Cao Y, Cao M, Wang Y, Cao Y, Gong T. Nanomedicine in cancer therapy. Signal Transduct Target Ther. 2023;8:1–34. https://doi.org/10.1038/s41392-023-01536-y.
Google Scholar
Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011;63:136–51. https://doi.org/10.1016/j.addr.2010.04.009.
Google Scholar
Maeda H. Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. J Control Release. 2012;164:138–44. https://doi.org/10.1016/j.jconrel.2012.04.038.
Google Scholar
Wang Y, Zhou Q, Luo W, Yang X, Zhang J, Lou Y, et al. A collagenase-decorated Cu-based nanotheranostics: remodeling extracellular matrix for optimizing cuproptosis and MRI in pancreatic ductal adenocarcinoma. J Nanobiotechnol. 2024;22:689. https://doi.org/10.1186/s12951-024-02968-6.
Google Scholar
Abdel-Hafez SM, Gallei M, Wagner S, Schneider M. Inhalable nano-structured microparticles for extracellular matrix modulation as a potential delivery system for lung cancer. Eur J Pharm Biopharm. 2024;204:114512. https://doi.org/10.1016/j.ejpb.2024.114512.
Google Scholar
Liu Q, Zou J, Chen Z, He W, Wu W. Current research trends of nanomedicines. Acta Pharm Sin B. 2023;13:4391–416. https://doi.org/10.1016/j.apsb.2023.05.018.
Google Scholar
Koo H, Huh MS, Sun I-C, Yuk SH, Choi K, Kim K, et al. In vivo targeted delivery of nanoparticles for theranosis. Acc Chem Res. 2011;44:1018–28. https://doi.org/10.1021/ar2000138.
Google Scholar
Janib SM, Moses AS, MacKay JA. Imaging and drug delivery using theranostic nanoparticles. Adv Drug Deliv Rev. 2010;62:1052–63. https://doi.org/10.1016/j.addr.2010.08.004.
Google Scholar
Bae YH, Park K. Targeted drug delivery to tumors: myths, reality and possibility. J Control Release. 2011;153:198–205. https://doi.org/10.1016/j.jconrel.2011.06.001.
Google Scholar
Zinger A, Koren L, Adir O, Poley M, Alyan M, Yaari Z, et al. Collagenase nanoparticles enhance the penetration of drugs into pancreatic tumors. ACS Nano. 2019;13:11008–21. https://doi.org/10.1021/acsnano.9b02395.
Google Scholar
Liu X, Dong X, Peng Z, Wang C, Wan J, Chen M, et al. Collagenase-functionalized liposomes based on enhancing penetration into the extracellular matrix augment therapeutic effect on idiopathic pulmonary fibrosis. AAPS PharmSciTech. 2025;26:113. https://doi.org/10.1208/s12249-025-03112-9.
Google Scholar
Zhou L, Liang Q, Li Y, Cao Y, Li J, Yang J, et al. Collagenase-I decorated co-delivery micelles potentiate extracellular matrix degradation and hepatic stellate cell targeting for liver fibrosis therapy. Acta Biomater. 2022;152:235–54. https://doi.org/10.1016/j.actbio.2022.08.065.
Google Scholar
Yu B, Wang W, Zhang Y, Sun Y, Li C, Liu Q, et al. Enhancing the tumor penetration of multiarm polymers by collagenase modification. Biomater Sci. 2024;12:2302–11. https://doi.org/10.1039/D3BM02123H.
Google Scholar
Xu F, Huang X, Wang Y, Zhou S. A size-changeable collagenase-modified nanoscavenger for increasing penetration and retention of nanomedicine in deep tumor tissue. Adv Mater. 2020;32:1906745. https://doi.org/10.1002/adma.201906745.
Google Scholar
Wang J, Wu Q, Wang Y, Xiang L, Feng J, Zhou Z, et al. Collagenase-loaded pH-sensitive nanocarriers efficiently remodeled tumor stroma matrixes and improved the enrichment of nanomedicines. Nanoscale. 2021;13:9402–14. https://doi.org/10.1039/D1NR00950H.
Google Scholar
Liu Q, Wang L, Su Y, Dong W, Wang H, Liu Y, et al. Ultrahigh Enzyme Loading Metal-Organic Frameworks for Deep Tissue Pancreatic Cancer Photoimmunotherapy. Small. 2024;20:e2305131. https://doi.org/10.1002/smll.202305131.
Google Scholar
Abucafy MP, Galvao Frem RC, Polinario G, Pavan FR, Zhao H, Mielcarek A, et al. MIL-100(Fe) sub-micrometric capsules as a dual drug delivery system. Int J Mol Sci. 2022;23:7670. https://doi.org/10.3390/ijms23147670.
Google Scholar
Oh JY, Seu M-S, Barui AK, Ok HW, Kim D, Choi E, et al. A multifunctional protein pre-coated metal–organic framework for targeted delivery with deep tissue penetration. Nanoscale. 2024;16:14748–56. https://doi.org/10.1039/D4NR02345E.
Google Scholar
Deng B, Huang R, Liang R, Fei Y, Luo Q, Song G. Design and evaluation of collagenase-loaded nanoparticles for mechanical intervention of orthotopic hepatocellular carcinoma in rat model. Int J Biol Macromol. 2025;285:138311. https://doi.org/10.1016/j.ijbiomac.2024.138311.
Google Scholar
Li J, Gong C, Chen X, Guo H, Tai Z, Ding N, et al. Biomimetic liposomal nanozymes improve breast cancer chemotherapy with enhanced penetration and alleviated hypoxia. J Nanobiotechnol. 2023;21(1):123. https://doi.org/10.1186/s12951-023-01874-7.
Google Scholar
Luo J, Cao J, Ma G, Wang X, Sun Y, Zhang C, et al. Collagenase-loaded H-TiO2 nanoparticles enhance ultrasound imaging-guided sonodynamic therapy in a pancreatic carcinoma xenograft model via digesting stromal barriers. ACS Appl Mater Interfaces. 2022;14:40535–45. https://doi.org/10.1021/acsami.2c08951.
Google Scholar
Maksoudian C, Izci M, Salembier R, Gilabert IP, Gonçalves FR, Luci CR, et al. Gold nanoparticle delivery to solid tumors by macrophage depletion, hypoxia inhibition, and collagen degradation. ACS Appl Nano Mater. 2023;6:7605–18. https://doi.org/10.1021/acsanm.3c00780.
Google Scholar
Murty S, Gilliland T, Qiao P, Tabtieng T, Higbee E, Al ZA, et al. Nanoparticles Functionalized with Collagenase Exhibit Improved Tumor Accumulation in a Murine Xenograft Model. Part Part Syst Charact. 2014;31:1307–12. https://doi.org/10.1002/ppsc.201400169.
Google Scholar
Yang X-Y, Zhang J-G, Zhou Q-M, Yu J-N, Lu Y-F, Wang X-J, et al. Extracellular matrix modulating enzyme functionalized biomimetic Au nanoplatform-mediated enhanced tumor penetration and synergistic antitumor therapy for pancreatic cancer. J Nanobiotechnology. 2022;20:524. https://doi.org/10.1186/s12951-022-01738-6.
Google Scholar
Pan A, Zhaoyang W, Binlong C, Wenbing D, Hua Z, Bing H, et al. Localized co-delivery of collagenase and trastuzumab by thermosensitive hydrogels for enhanced antitumor efficacy in human breast xenograft. Drug Deliv. 2018;25:1495–503. https://doi.org/10.1080/10717544.2018.1474971.
Google Scholar
Corder RD, Gadi SV, Vachieri RB, Jayes FL, Cullen JM, Khan SA, et al. Using rheology to quantify the effects of localized collagenase treatments on uterine fibroid digestion. Acta Biomater. 2021;134:443–52. https://doi.org/10.1016/j.actbio.2021.08.003.
Google Scholar
Chen Y, Fan Z, Xu W, Zhu Z, Tan Z, Hu Y, et al. An injectable nanocomposite hydrogel with deep penetration ability for enhanced photothermal and chemotherapy. J Colloid Interface Sci. 2025;685:268–79. https://doi.org/10.1016/j.jcis.2025.01.146.
Google Scholar
Yang C, Liao X, Zhou K, Yao Y, He X, Zhong W, et al. Multifunctional nanoparticles and collagenase dual loaded thermosensitive hydrogel system for enhanced tumor-penetration, reversed immune suppression and photodynamic-immunotherapy. Bioact Mater. 2025;48:1–17. https://doi.org/10.1016/j.bioactmat.2025.02.014.
Google Scholar
Jansen CA, Cruijsen CWA, de Ruiter T, Nanlohy N, Willems N, Janssens-Korpela P, et al. Regulated expression of the inhibitory receptor LAIR-1 on human peripheral T cells during T cell activation and differentiation. Eur J Immunol. 2007;37:914–24. https://doi.org/10.1002/eji.200636678.
Google Scholar
Kohli AG, Kivimäe S, Tiffany MR, Szoka FC. Improving the distribution of Doxil® in the tumor matrix by depletion of tumor hyaluronan. J Control Release. 2014;191:105–14. https://doi.org/10.1016/j.jconrel.2014.05.019.
Google Scholar
Kohli AG, Kierstead PH, Venditto VJ, Walsh CL, Szoka FC. Designer lipids for drug delivery: from heads to tails. J Control Release. 2014;190:274–87. https://doi.org/10.1016/j.jconrel.2014.04.047.
Google Scholar
Rezvantalab S, Drude NI, Moraveji MK, Güvener N, Koons EK, Shi Y, et al. PLGA-based nanoparticles in cancer treatment. Front Pharmacol. 2018. https://doi.org/10.3389/fphar.2018.01260.
Google Scholar
Narmani A, Jahedi R, Bakhshian-Dehkordi E, Ganji S, Nemati M, Ghahramani-Asl R, et al. Biomedical applications of PLGA nanoparticles in nanomedicine: advances in drug delivery systems and cancer therapy. Expert Opin Drug Deliv. 2023;20:937–54. https://doi.org/10.1080/17425247.2023.2223941.
Google Scholar
Kalyane D, Raval N, Maheshwari R, Tambe V, Kalia K, Tekade RK. Employment of enhanced permeability and retention effect (EPR): nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer. Mater Sci Eng C Mater Biol Appl. 2019;98:1252–76. https://doi.org/10.1016/j.msec.2019.01.066.
Google Scholar
Li B, Wen H-M, Cui Y, Zhou W, Qian G, Chen B. Emerging multifunctional metal-organic framework materials. Adv Mater. 2016;28:8819–60. https://doi.org/10.1002/adma.201601133.
Google Scholar
Bétard A, Fischer RA. Metal-organic framework thin films: from fundamentals to applications. Chem Rev. 2012;112:1055–83. https://doi.org/10.1021/cr200167v.
Google Scholar
Zhang Q, Kuang G, Li W, Wang J, Ren H, Zhao Y. Stimuli-responsive gene delivery nanocarriers for cancer therapy. Nano-Micro Lett. 2023;15:44. https://doi.org/10.1007/s40820-023-01018-4.
Google Scholar
Li Y, Dong H, Wang K, Shi D, Zhang X, Zhuo R. Stimulus-responsive polymeric nanoparticles for biomedical applications. Sci China Chem. 2010;53:447–57. https://doi.org/10.1007/s11426-010-0101-4.
Google Scholar
Mi P. Stimuli-responsive nanocarriers for drug delivery, tumor imaging, therapy and theranostics. Theranostics. 2020;10:4557–88. https://doi.org/10.7150/thno.38069.
Google Scholar
Hajebi S, Rabiee N, Bagherzadeh M, Ahmadi S, Rabiee M, Roghani-Mamaqani H, et al. Stimulus-responsive polymeric nanogels as smart drug delivery systems. Acta Biomater. 2019;92:1–18. https://doi.org/10.1016/j.actbio.2019.05.018.
Google Scholar
Wei D, Sun Y, Zhu H, Fu Q. Stimuli-responsive polymer-based nanosystems for cancer theranostics. ACS Nano. 2023;17:23223–61. https://doi.org/10.1021/acsnano.3c06019.
Google Scholar
Zou M, Shen C, Peng W, Zhang L, Liu W, Lv Y. A biomimetic nanoplatform with mechano-metabolic microenvironment and hypoxic microenvironment programming ability for enhanced chemo-immunotherapy. Chem Eng J. 2025;513:163088. https://doi.org/10.1016/j.cej.2025.163088.
Google Scholar
Kuhn SJ, Finch SK, Hallahan DE, Giorgio TD. Proteolytic surface functionalization enhances in vitro magnetic nanoparticle mobility through extracellular matrix. Nano Lett. 2006;6:306–12. https://doi.org/10.1021/nl052241g.
Google Scholar
Mauro N, Scialabba C, Puleio R, Varvara P, Licciardi M, Cavalaro G, et al. SPIONs embedded in polyamino acid nanogels to synergistically treat tumor microenvironment and breast cancer cells. Int J Pharm. 2019;555:207–19. https://doi.org/10.1016/j.ijpharm.2018.11.046.
Google Scholar
Yin T, Chen H, Ma A, Pan H, Chen Z, Tang X, et al. Cleavable collagenase-assistant nanosonosensitizer for tumor penetration and sonodynamic therapy. Biomaterials. 2023;293:121992. https://doi.org/10.1016/j.biomaterials.2022.121992.
Google Scholar
Sun R, Zhang Y, Piao Y, Xiang J, Shao S, Zhou Q, et al. Dual enzyme-responsive polymer-drug conjugates induce diverse cells mutual transcytosis to achieve deep pancreatic tumor penetration. Angew Chem Int Ed Engl. 2025. https://doi.org/10.1002/anie.202506038.
Google Scholar
LeBeau AM, Brennen WN, Aggarwal S, Denmeade SR. Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin. Mol Cancer Ther. 2009;8:1378–86. https://doi.org/10.1158/1535-7163.MCT-08-1170.
Google Scholar
Brennen WN, Rosen DM, Wang H, Isaacs JT, Denmeade SR. Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug. JNCI J Natl Cancer Inst. 2012;104:1320–34. https://doi.org/10.1093/jnci/djs336.
Google Scholar
Zana A, Galbiati A, Gilardoni E, Bocci M, Millul J, Sturm T, et al. Fibroblast activation protein triggers release of drug payload from non-internalizing small molecule drug conjugates in solid tumors. Clin Cancer Res. 2022;28:5440–54. https://doi.org/10.1158/1078-0432.CCR-22-1788.
Google Scholar
Li Z, Mo F, Guo K, Ren S, Wang Y, Chen Y, et al. Nanodrug-bacteria conjugates-mediated oncogenic collagen depletion enhances immune checkpoint blockade therapy against pancreatic cancer. Med. 2024;5:348-367.e7. https://doi.org/10.1016/j.medj.2024.02.012.
Google Scholar
Qi L, Duan B-W, Wang H, Liu Y-J, Han H, Han M-M, et al. Reactive oxygen species-responsive nanoparticles toward extracellular matrix normalization for pancreatic fibrosis regression. Adv Sci. 2024;11:2401254. https://doi.org/10.1002/advs.202401254.
Google Scholar
Zhou D, Duan Z, Li Z, Ge F, Wei R, Kong L. The significance of glycolysis in tumor progression and its relationship with the tumor microenvironment. Front Pharmacol. 2022. https://doi.org/10.3389/fphar.2022.1091779.
Google Scholar
Abaza M, Luqmani YA. The influence of pH and hypoxia on tumor metastasis. Expert Rev Anticancer Ther. 2013;13:1229–42. https://doi.org/10.1586/14737140.2013.843455.
Google Scholar
Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018;15:325–40. https://doi.org/10.1038/nrclinonc.2018.29.
Google Scholar
Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell. 2014;26(5):605–22. https://doi.org/10.1016/j.ccell.2014.10.006.
Google Scholar
Zhang X, Lin Y, Gillies RJ. Tumor pH and its measurement. J Nucl Med. 2010;51:1167–70. https://doi.org/10.2967/jnumed.109.068981.
Google Scholar
Gilkes DM, Semenza GL, Wirtz D. Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat Rev Cancer. 2014;14:430–9. https://doi.org/10.1038/nrc3726.
Google Scholar
Ji F, Wang Y, Qiu L, Li S, Zhu J, Liang Z, et al. Hypoxia inducible factor 1α-mediated LOX expression correlates with migration and invasion in epithelial ovarian cancer. Int J Oncol. 2013;42:1578–88. https://doi.org/10.3892/ijo.2013.1878.
Google Scholar
Januzzi JL, Garasic JM, Kasner SE, McDonald V, Petrie MC, Seltzer J, et al. Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee. J Hematol Oncol. 2022;15:1. https://doi.org/10.1186/s13045-021-01221-z.
Google Scholar
Fais S, Venturi G, Gatenby B. Microenvironmental acidosis in carcinogenesis and metastases: new strategies in prevention and therapy. Cancer Metastasis Rev. 2014;33:1095–108. https://doi.org/10.1007/s10555-014-9531-3.
Google Scholar
Lee S-H, McIntyre D, Honess D, Hulikova A, Pacheco-Torres J, Cerdán S, et al. Carbonic anhydrase IX is a pH-stat that sets an acidic tumour extracellular pH in vivo. Br J Cancer. 2018;119:622–30. https://doi.org/10.1038/s41416-018-0216-5.
Google Scholar
Büscheck F, Fraune C, Simon R, Kluth M, Hube-Magg C, Möller-Koop C, et al. Aberrant expression of membranous carbonic anhydrase IX (CAIX) is associated with unfavorable disease course in papillary and clear cell renal cell carcinoma. Urol Oncol Semin Orig Investig. 2018;36:531.e19-531.e25. https://doi.org/10.1016/j.urolonc.2018.08.015.
Google Scholar
Panisova E, Kery M, Sedlakova O, Brisson L, Debreova M, Sboarina M, et al. Lactate stimulates CA IX expression in normoxic cancer cells. Oncotarget. 2017;8:77819–35. https://doi.org/10.18632/oncotarget.20836.
Google Scholar
Vaupel P, Multhoff G. Fatal Alliance of Hypoxia-/HIF-1α-Driven Microenvironmental Traits Promoting Cancer Progression. Oxyg Transp Tissue XLI. 2020. https://doi.org/10.1007/978-3-030-34461-0_21.
Google Scholar
Gonzalez-Avila G, Sommer B, Flores-Soto E, Aquino-Galvez A. Hypoxic effects on matrix metalloproteinases’ expression in the tumor microenvironment and therapeutic perspectives. Int J Mol Sci. 2023;24:16887. https://doi.org/10.3390/ijms242316887.
Google Scholar
Springer M, Burakgazi ZA, Domukhovska A, Nafchi B, Beary MC, Acquisto A, et al. HIF-1α-mediated disruption of cellular junctions: the impact of hypoxia on the tumor microenvironment and invasion. Int J Mol Sci. 2025;26:5101. https://doi.org/10.3390/ijms26115101.
Google Scholar
Zhang Y, Zhai Z, Duan J, Wang X, Zhong J, Wu L, et al. Lactate: the mediator of metabolism and immunosuppression. Front Endocrinol (Lausanne). 2022. https://doi.org/10.3389/fendo.2022.901495.
Google Scholar
Zhou Y, Lou J, Tian Y, Ding J, Wang X, Tang B. How lactate affects immune strategies in lymphoma. Front Mol Biosci. 2024. https://doi.org/10.3389/fmolb.2024.1480884.
Google Scholar
Rahman MA, Yadab MK, Ali MM. Emerging role of extracellular pH in tumor microenvironment as a therapeutic target for cancer immunotherapy. Cells. 2024;13:1924. https://doi.org/10.3390/cells13221924.
Google Scholar
Saadat M, Mostafaei F, Mahdinloo S, Abdi M, Zahednezhad F, Zakeri-Milani P, et al. Drug delivery of pH-sensitive nanoparticles into the liver cancer cells. J Drug Deliv Sci Technol. 2021;63:102557. https://doi.org/10.1016/j.jddst.2021.102557.
Google Scholar
Lim E-K, Chung BH, Chung SJ. Recent advances in pH-sensitive polymeric nanoparticles for smart drug delivery in cancer therapy. Curr Drug Targets. 2018;19:300–17. https://doi.org/10.2174/1389450117666160602202339.
Google Scholar
Zhang J, Zheng Y, Xie X, Wang L, Su Z, Wang Y, et al. Cleavable multifunctional targeting mixed micelles with sequential pH-triggered TAT peptide activation for improved antihepatocellular carcinoma efficacy. Mol Pharm. 2017;14:3644–59. https://doi.org/10.1021/acs.molpharmaceut.7b00404.
Google Scholar
Zhang C, An T, Wang D, Wan G, Zhang M, Wang H, et al. Stepwise pH-responsive nanoparticles containing charge-reversible pullulan-based shells and poly(β-amino ester)/poly(lactic-co-glycolic acid) cores as carriers of anticancer drugs for combination therapy on hepatocellular carcinoma. J Control Release. 2016;226:193–204. https://doi.org/10.1016/j.jconrel.2016.02.030.
Google Scholar
Zheng S, Wang J, Ding N, Chen W, Chen H, Xue M, et al. Prodrug polymeric micelles integrating cancer-associated fibroblasts deactivation and synergistic chemotherapy for gastric cancer. J Nanobiotechnol. 2021;19:381. https://doi.org/10.1186/s12951-021-01127-5.
Google Scholar
Mesoporous silica nanoparticles. facile surface functionalization and versatile biomedical applications in oncology. Acta Biomater. 2020;116:1–15. https://doi.org/10.1016/j.actbio.2020.09.009.
Google Scholar
Narayan R, Nayak UY, Raichur AM, Garg S. Mesoporous silica nanoparticles: a comprehensive review on synthesis and recent advances. Pharmaceutics. 2018;10:118. https://doi.org/10.3390/pharmaceutics10030118.
Google Scholar
Gu J, Su S, Zhu M, Li Y, Zhao W, Duan Y, et al. Targeted doxorubicin delivery to liver cancer cells by PEGylated mesoporous silica nanoparticles with a pH-dependent release profile. Microporous Mesoporous Mater. 2012;161:160–7. https://doi.org/10.1016/j.micromeso.2012.05.035.
Google Scholar
Li M, Zhao G, Su W-K, Shuai Q. Enzyme-responsive nanoparticles for anti-tumor drug delivery. Front Chem. 2020. https://doi.org/10.3389/fchem.2020.00647.
Google Scholar
Shahriari M, Zahiri M, Abnous K, Taghdisi SM, Ramezani M, Alibolandi M. Enzyme responsive drug delivery systems in cancer treatment. J Control Release. 2019;308:172–89. https://doi.org/10.1016/j.jconrel.2019.07.004.
Google Scholar
Kuang T, Liu Y, Gong T, Peng X, Hu X, Yu Z. Enzyme-responsive nanoparticles for anticancer drug delivery. Curr Nanosci. 2015;12:38–46. https://doi.org/10.2174/1573413711666150624170518.
Google Scholar
Zhao X, Wang T, Liu W, Wang C, Wang D, Shang T, et al. Multifunctional Au@IPN-pNIPAAm nanogels for cancer cell imaging and combined chemo-photothermal treatment. J Mater Chem. 2011;21:7240–7. https://doi.org/10.1039/C1JM10277J.
Google Scholar
Shang T, Wang C, Ren L, Tian X, Li D, Ke X, et al. Synthesis and characterization of NIR-responsive Aurod@pNIPAAm-PEGMA nanogels as vehicles for delivery of photodynamic therapy agents. Nanoscale Res Lett. 2013;8:4. https://doi.org/10.1186/1556-276X-8-4.
Google Scholar
Heskins M, Guillet JE. Solution properties of poly(N-isopropylacrylamide). Journal of Macromolecular Science: Part A. 1968;2:1441–55. https://doi.org/10.1080/10601326808051910.
Google Scholar
Tauer K, Gau D, Schulze S, Völkel A, Dimova R. Thermal property changes of poly(N-isopropylacrylamide) microgel particles and block copolymers. Colloid Polym Sci. 2009;287:299–312. https://doi.org/10.1007/s00396-008-1984-x.
Google Scholar
Van Durme K, Van Assche G, Van Mele B. Kinetics of demixing and remixing in poly(N-isopropylacrylamide)/water studied by modulated temperature DSC. Macromolecules. 2004;37:9596–605. https://doi.org/10.1021/ma048472b.
Google Scholar
Sung B, Kim C, Kim M-H. Biodegradable colloidal microgels with tunable thermosensitive volume phase transitions for controllable drug delivery. J Colloid Interface Sci. 2015;450:26–33. https://doi.org/10.1016/j.jcis.2015.02.068.
Google Scholar
Materón EM, Miyazaki CM, Carr O, Joshi N, Picciani PHS, Dalmaschio CJ, et al. Magnetic nanoparticles in biomedical applications: a review. Applied Surface Science Advances. 2021;6:100163. https://doi.org/10.1016/j.apsadv.2021.100163.
Google Scholar
Rezaei B, Yari P, Sanders SM, Wang H, Chugh VK, Liang S, et al. Magnetic Nanoparticles: A Review on Synthesis, Characterization, Functionalization, and Biomedical Applications. Small. 2024;20:e2304848. https://doi.org/10.1002/smll.202304848.
Google Scholar
Zewail MB, Yang G, Fan Y, Hui Y, Zhao C-X, Liu Y. Cell membrane-coated lipid nanoparticles for drug delivery. Aggregate. 2025. https://doi.org/10.1002/agt2.70054.
Google Scholar
Alimohammadvand S, Kaveh Zenjanab M, Mashinchian M, Shayegh J, Jahanban-Esfahlan R. Recent advances in biomimetic cell membrane–camouflaged nanoparticles for cancer therapy. Biomed Pharmacother. 2024;177:116951. https://doi.org/10.1016/j.biopha.2024.116951.
Google Scholar
Zhang Y, Zhang Q, Li C, Zhou Z, Lei H, Liu M, et al. Advances in cell membrane-based biomimetic nanodelivery systems for natural products. Drug Deliv. 2024;31:2361169. https://doi.org/10.1080/10717544.2024.2361169.
Google Scholar
Li B, Fei W, Lijuan G, Qing H, Yuxin Y, Chen H. The Potential of Biomimetic Nanoparticles for Tumor-Targeted Drug Delivery. Nanomedicine. 2018;13:2099–118. https://doi.org/10.2217/nnm-2018-0017.
Google Scholar
Tan A, Rajadas J, Seifalian AM. Exosomes as nano-theranostic delivery platforms for gene therapy. Adv Drug Deliv Rev. 2013;65:357–67. https://doi.org/10.1016/j.addr.2012.06.014.
Google Scholar
Sun D, Zhuang X, Zhang S, Deng Z-B, Grizzle W, Miller D, et al. Exosomes are endogenous nanoparticles that can deliver biological information between cells. Adv Drug Deliv Rev. 2013;65:342–7. https://doi.org/10.1016/j.addr.2012.07.002.
Google Scholar
Shi Y, Zhang J, Li Y, Feng C, Shao C, Shi Y, et al. Engineered mesenchymal stem/stromal cells against cancer. Cell Death Dis. 2025;16:113. https://doi.org/10.1038/s41419-025-07443-0.
Google Scholar
Minev T, Balbuena S, Gill JM, Marincola FM, Kesari S, Lin F. Mesenchymal stem cells – the secret agents of cancer immunotherapy: promises, challenges, and surprising twists. Oncotarget. 2024;15:793–805. https://doi.org/10.18632/oncotarget.28672.
Google Scholar
Pegtel DM, Gould SJ. Exosomes. Annu Rev Biochem. 2019;88:487–514. https://doi.org/10.1146/annurev-biochem-013118-111902.
Google Scholar
Mathivanan S, Ji H, Simpson RJ. Exosomes: extracellular organelles important in intercellular communication. J Proteomics. 2010;73:1907–20. https://doi.org/10.1016/j.jprot.2010.06.006.
Google Scholar
Freitas C, Sousa C, Machado F, Serino M, Santos V, Cruz-Martins N, et al. The role of liquid biopsy in early diagnosis of lung cancer. Front Oncol. 2021. https://doi.org/10.3389/fonc.2021.634316.
Google Scholar
Baig MS, Roy A, Rajpoot S, Liu D, Savai R, Banerjee S, et al. Tumor-derived exosomes in the regulation of macrophage polarization. Inflamm Res. 2020;69:435–51. https://doi.org/10.1007/s00011-020-01318-0.
Google Scholar
Long L, Zhang X, Bai J, Li Y, Wang X, Zhou Y.
Tissue-specific and exosomal miRNAs in lung cancer radiotherapy: from regulatory mechanisms to clinical implications
. Cancer Manag Res. 2019;11:4413–24. https://doi.org/10.2147/CMAR.S198966.
Google Scholar
Hakulinen J, Sankkila L, Sugiyama N, Lehti K, Keski-Oja J. Secretion of active membrane type 1 matrix metalloproteinase (MMP-14) into extracellular space in microvesicular exosomes. J Cell Biochem. 2008;105:1211–8. https://doi.org/10.1002/jcb.21923.
Google Scholar
Sanderson RD, Bandari SK, Vlodavsky I. Proteases and glycosidases on the surface of exosomes: newly discovered mechanisms for extracellular remodeling. Matrix Biol. 2019;75:160–9. https://doi.org/10.1016/j.matbio.2017.10.007.
Google Scholar
Li T, Yan Y, Wang B, Qian H, Zhang X, Shen L, et al. Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis. Stem Cells Dev. 2013;22:845–54. https://doi.org/10.1089/scd.2012.0395.
Google Scholar
Zhao B, Shi X, Feng D, Han J, Hu D. MicroRNA let-7d attenuates hypertrophic scar fibrosis through modulation of iron metabolism by reducing DMT1 expression. J Mol Histol. 2023;54:77–87. https://doi.org/10.1007/s10735-023-10113-0.
Google Scholar
Yin F, Wang W-Y, Mao L-C, Cai Q-Q, Jiang W-H. Effect of human umbilical cord mesenchymal stem cells transfected with HGF on TGF-β1/Smad signaling pathway in carbon tetrachloride-induced liver fibrosis rats. Stem Cells Dev. 2020;29:1395–406. https://doi.org/10.1089/scd.2020.0060.
Google Scholar
Yang J, Hu H, Zhang S, Jiang L, Cheng Y, Xie H, et al. Human umbilical cord mesenchymal stem cell-derived exosomes alleviate pulmonary fibrosis in mice by inhibiting epithelial-mesenchymal transition. Nan Fang Yi Ke Da Xue Xue Bao. 2020;40:988–94. https://doi.org/10.2122/j.issn.1673-4254.2020.07.11.
Google Scholar
Baglio SR, Pegtel DM, Baldini N. Mesenchymal stem cell secreted vesicles provide novel opportunities in (stem) cell-free therapy. Front Physiol. 2012;3:359. https://doi.org/10.3389/fphys.2012.00359.
Google Scholar
Lou G, Chen Z, Zheng M, Liu Y. Mesenchymal stem cell-derived exosomes as a new therapeutic strategy for liver diseases. Exp Mol Med. 2017;49:e346. https://doi.org/10.1038/emm.2017.63.
Google Scholar
Li J, Ghazwani M, Zhang Y, Lu J, Li J, Fan J, et al. MiR-122 regulates collagen production via targeting hepatic stellate cells and suppressing P4HA1 expression. J Hepatol. 2013;58:522–8. https://doi.org/10.1016/j.jhep.2012.11.011.
Google Scholar
Milosavljevic N, Gazdic M, Simovic Markovic B, Arsenijevic A, Nurkovic J, Dolicanin Z, et al. Mesenchymal stem cells attenuate liver fibrosis by suppressing Th17 cells – an experimental study. Transplant Int. 2018;31(1):102–15. https://doi.org/10.1111/tri.13023.
Google Scholar
Dooley S, ten Dijke P. TGF-β in progression of liver disease. Cell Tissue Res. 2012;347:245–56. https://doi.org/10.1007/s00441-011-1246-y.
Google Scholar
Brenner DA. Transforming growth factor B and hepatic fibrosis: cause or effect? Hepatology. 1991;14:740–2.
Google Scholar
Arias M, Lahme B, Van de Leur E, Gressner AM, Weiskirchen R. Adenoviral delivery of an antisense RNA complementary to the 3’ coding sequence of transforming growth factor-beta1 inhibits fibrogenic activities of hepatic stellate cells. Cell Growth Differ. 2002;13:265–73.
Google Scholar
Liu X, Wang H, Yang M, Hou Y, Chen Y, Bie P. Exosomal miR-29b from cancer-associated fibroblasts inhibits the migration and invasion of hepatocellular carcinoma cells. Transl Cancer Res. 2020. https://doi.org/10.21037/tcr.2020.02.68.
Google Scholar
Fang J-H, Zhou H-C, Zeng C, Yang J, Liu Y, Huang X, et al. Microrna-29b suppresses tumor angiogenesis, invasion, and metastasis by regulating matrix metalloproteinase 2 expression. Hepatology. 2011;54:1729–40. https://doi.org/10.1002/hep.24577.
Google Scholar
Forbes SJ, Gupta S, Dhawan A. Cell therapy for liver disease: From liver transplantation to cell factory. J Hepatol. 2015;62:S157–69. https://doi.org/10.1016/j.jhep.2015.02.040.
Google Scholar
Trombino S, Servidio C, Curcio F, Cassano R. Strategies for hyaluronic acid-based hydrogel design in drug delivery. Pharmaceutics. 2019;11:407. https://doi.org/10.3390/pharmaceutics11080407.
Google Scholar
Fan S, Liu Q, Dong J, Ai X, Li J, Huang W, et al. In situ forming an injectable hyaluronic acid hydrogel for drug delivery and synergistic tumor therapy. Heliyon. 2024;10:e32135. https://doi.org/10.1016/j.heliyon.2024.e32135.
Google Scholar
Kim JH, Moon MJ, Kim DY, Heo SH, Jeong YY. Hyaluronic acid-based nanomaterials for cancer therapy. Polymers. 2018;10:1133. https://doi.org/10.3390/polym10101133.
Google Scholar
Qin Y, Geng X, Sun Y, Zhao Y, Chai W, Wang X, et al. Ultrasound nanotheranostics: toward precision medicine. J Control Release. 2023;353:105–24. https://doi.org/10.1016/j.jconrel.2022.11.021.
Google Scholar
Son S, Kim JH, Wang X, Zhang C, Yoon SA, Shin J, et al. Multifunctional sonosensitizers in sonodynamic cancer therapy. Chem Soc Rev. 2020;49:3244–61. https://doi.org/10.1039/C9CS00648F.
Google Scholar
Zhang Y, Zhang X, Yang H, Yu L, Xu Y, Sharma A, et al. Advanced biotechnology-assisted precise sonodynamic therapy. Chem Soc Rev. 2021;50:11227–48. https://doi.org/10.1039/D1CS00403D.
Google Scholar
Continuous inertial cavitation evokes massive ROS for reinforcing sonodynamic therapy and immunogenic cell death against breast carcinoma. Nano Today. 2021;36:101009. https://doi.org/10.1016/j.nantod.2020.101009
Wang H, Guo J, Lin W, Fu Z, Ji X, Yu B, et al. Open-shell nanosensitizers for glutathione responsive cancer sonodynamic therapy. Adv Mater. 2022;34:2110283. https://doi.org/10.1002/adma.202110283.
Google Scholar
Zheng X, Goins BA, Cameron IL, Santoyo C, Bao A, Frohlich VC, et al. Ultrasound-guided intratumoral administration of collagenase-2 improved liposome drug accumulation in solid tumor xenografts. Cancer Chemother Pharmacol. 2011;67:173–82. https://doi.org/10.1007/s00280-010-1305-1.
Google Scholar
Brennen WN, Isaacs JT, Denmeade SR. Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Mol Cancer Ther. 2012;11:257–66. https://doi.org/10.1158/1535-7163.MCT-11-0340.
Google Scholar
Koczorowska Mm, Tholen S, Bucher F, Lutz L, Kizhakkedathu Jn, De Wever O, et al. Fibroblast activation protein-α, a stromal cell surface protease, shapes key features of cancer associated fibroblasts through proteome and degradome alterations. Mol Oncol. 2016;10:40–58. https://doi.org/10.1016/j.molonc.2015.08.001.
Google Scholar
Nissen NI, Karsdal M, Willumsen N. Collagens and cancer associated fibroblasts in the reactive stroma and its relation to cancer biology. J Exp Clin Cancer Res. 2019;38:115. https://doi.org/10.1186/s13046-019-1110-6.
Google Scholar
Levy MT, McCaughan GW, Abbott CA, Park JE, Cunningham AM, Müller E, et al. Fibroblast activation protein: a cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis. Hepatology. 1999;29:1768–78. https://doi.org/10.1002/hep.510290631.
Google Scholar
Meng S, Hara T, Miura Y, Ishii H. Fibroblast activation protein constitutes a novel target of chimeric antigen receptor T-cell therapy in solid tumors. Cancer Sci. 2024;115:3532–42. https://doi.org/10.1111/cas.16285.
Google Scholar
Garin-Chesa P, Old LJ, Rettig WJ. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci U S A. 1990;87:7235–9. https://doi.org/10.1073/pnas.87.18.7235.
Google Scholar
Rettig WJ, Garin-Chesa P, Healey JH, Su SL, Ozer HL, Schwab M, et al. Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin. Cancer Res. 1993;53:3327–35. http://www.ncbi.nlm.nih.gov/pubmed/8391923
Brennen WN, Thorek JDL, Jiang W, Krueger TE, Antony L, Denmeade SR, et al. Overcoming stromal barriers to immuno-oncological responses via fibroblast activation protein-targeted therapy. Immunotherapy. 2021;13:155–75. https://doi.org/10.2217/imt-2020-0066.
Google Scholar
Fang J, Xiao L, Joo K-I, Liu Y, Zhang C, Liu S, et al. A potent immunotoxin targeting fibroblast activation protein for treatment of breast cancer in mice. Int J Cancer. 2016;138:1013–23. https://doi.org/10.1002/ijc.29831.
Google Scholar
Fang J, Hu B, Li S, Zhang C, Liu Y, Wang P. A multi-antigen vaccine in combination with an immunotoxin targeting tumor-associated fibroblast for treating murine melanoma. Mol Ther. 2016;3:16007. https://doi.org/10.1038/mto.2016.7.
Google Scholar
Xia Q, Zhang F-F, Geng F, Liu C-L, Xu P, Lu Z-Z, et al. Anti-tumor effects of DNA vaccine targeting human fibroblast activation protein α by producing specific immune responses and altering tumor microenvironment in the 4T1 murine breast cancer model. Cancer Immunol Immunother. 2016;65:613–24. https://doi.org/10.1007/s00262-016-1827-4.
Google Scholar
Duperret EK, Trautz A, Ammons D, Perales-Puchalt A, Wise MC, Yan J, et al. Alteration of the tumor stroma using a consensus DNA vaccine targeting fibroblast activation protein (FAP) synergizes with antitumor vaccine therapy in mice. Clin Cancer Res. 2018;24:1190–201. https://doi.org/10.1158/1078-0432.CCR-17-2033.
Google Scholar
Teng C, Zhang B, Yuan Z, Kuang Z, Chai Z, Ren L, et al. Fibroblast activation protein-α-adaptive micelles deliver anti-cancer drugs and reprogram stroma fibrosis. Nanoscale. 2020;12:23756–67. https://doi.org/10.1039/d0nr04465b.
Google Scholar
Zhang Y, Zhou J, Chen X, Li Z, Gu L, Pan D, et al. Modulating tumor-stromal crosstalk via a redox-responsive nanomedicine for combination tumor therapy. J Control Release. 2023;356:525–41. https://doi.org/10.1016/j.jconrel.2023.03.015.
Google Scholar
Zhou S, Zhen Z, Paschall AV, Xue L, Yang X, Bebin Blackwell A-G, et al. FAP-targeted photodynamic therapy mediated by ferritin nanoparticles elicits an immune response against cancer cells and cancer associated fibroblasts. Adv Funct Mater. 2021;31:2007017. https://doi.org/10.1002/adfm.202007017.
Google Scholar
Gao C, Jian C, Wang L, Liu Y, Xiong Y, Wu T, et al. FAP-targeting biomimetic nanosystem to restore the activated cancer-associated fibroblasts to quiescent state for breast cancer radiotherapy. Int J Pharm. 2025;670:125190. https://doi.org/10.1016/j.ijpharm.2025.125190.
Google Scholar
Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20:359–71. https://doi.org/10.1038/s41571-023-00754-1.
Google Scholar
Rao S, Kiick KL. Recent advances in extracellular matrix-inspired nanocarriers. Expert Opin Drug Deliv. 2025. https://doi.org/10.1080/17425247.2025.2519809.
Google Scholar
Peng L, Sferruzza G, Yang L, Zhou L, Chen S. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell Mol Immunol. 2024;21(10):1089–108. https://doi.org/10.1038/s41423-024-01207-0.
Google Scholar
Schuberth PC, Hagedorn C, Jensen SM, Gulati P, van den Broek M, Mischo A, et al. Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells. J Transl Med. 2013;11:187. https://doi.org/10.1186/1479-5876-11-187.
Google Scholar
Wang L-CS, Lo A, Scholler J, Sun J, Majumdar RS, Kapoor V, et al. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol Res. 2014;2:154–66. https://doi.org/10.1158/2326-6066.CIR-13-0027.
Google Scholar
Rodriguez-Garcia A, Palazon A, Noguera-Ortega E, Powell DJ, Guedan S. Car-T cells hit the tumor microenvironment: strategies to overcome tumor escape. Front Immunol. 2020;11:1109. https://doi.org/10.3389/fimmu.2020.01109.
Google Scholar
Roberts EW, Deonarine A, Jones JO, Denton AE, Feig C, Lyons SK, et al. Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemia. J Exp Med. 2013;210:1137–51. https://doi.org/10.1084/jem.20122344.
Google Scholar
Tran E, Chinnasamy D, Yu Z, Morgan RA, Lee C-CR, Restifo NP, et al. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J Exp Med. 2013;210:1125–35. https://doi.org/10.1084/jem.20130110.
Google Scholar
Loeffler M, Krüger JA, Niethammer AG, Reisfeld RA. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Investig. 2006;116:1955–62. https://doi.org/10.1172/JCI26532.
Google Scholar
Lee J, Fassnacht M, Nair S, Boczkowski D, Gilboa E. Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts. Cancer Res. 2005;65:11156–63. https://doi.org/10.1158/0008-5472.CAN-05-2805.
Google Scholar
Wen Y, Wang C-T, Ma T-T, Li Z-Y, Zhou L-N, Mu B, et al. Immunotherapy targeting fibroblast activation protein inhibits tumor growth and increases survival in a murine colon cancer model. Cancer Sci. 2010;101:2325–32. https://doi.org/10.1111/j.1349-7006.2010.01695.x.
Google Scholar
Kakarla S, Chow KKH, Mata M, Shaffer DR, Song X-T, Wu M-F, et al. Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Mol Ther. 2013;21:1611–20. https://doi.org/10.1038/mt.2013.110.
Google Scholar
Wang W, Hu K, Xue J, Chen J, Du X, Zhao T, et al. In vivo FAP-CAR macrophages enhance chemotherapy and immunotherapy against pancreatic cancer by removing the fibrosis barrier. J Control Release. 2025;384:113888. https://doi.org/10.1016/j.jconrel.2025.113888.
Google Scholar
Ruixin S, Yifan L, Yansha S, Min Z, Yiwei D, Xiaoli H, et al. Dual targeting chimeric antigen receptor cells enhance antitumour activity by overcoming T cell exhaustion in pancreatic cancer. Br J Pharmacol. 2024;181:4628–46. https://doi.org/10.1111/bph.16505.
Google Scholar
Augsten M. Cancer-Associated Fibroblasts as Another Polarized Cell Type of the Tumor Microenvironment. Front Oncol. 2014. https://doi.org/10.3389/fonc.2014.00062.
Google Scholar
Yoshida GJ. Regulation of heterogeneous cancer-associated fibroblasts: the molecular pathology of activated signaling pathways. J Exp Clin Cancer Res. 2020;39:112. https://doi.org/10.1186/s13046-020-01611-0.
Google Scholar
Chen C-Y, Yang S-H, Chang P-Y, Chen S-F, Nieh S, Huang W-Y, et al. Cancer-associated-fibroblast-mediated paracrine and autocrine SDF-1/CXCR4 signaling promotes stemness and aggressiveness of colorectal cancers. Cells. 2024;13:1334. https://doi.org/10.3390/cells13161334.
Google Scholar
Tan H-X, Gong W-Z, Zhou K, Xiao Z-G, Hou F-T, Huang T, et al. CXCR4/TGF-β1 mediated hepatic stellate cells differentiation into carcinoma-associated fibroblasts and promoted liver metastasis of colon cancer. Cancer Biol Ther. 2020;21:258–68. https://doi.org/10.1080/15384047.2019.1685157.
Google Scholar
Sugihara H, Ishimoto T, Yasuda T, Izumi D, Eto K, Sawayama H, et al. Cancer-associated fibroblast-derived CXCL12 causes tumor progression in adenocarcinoma of the esophagogastric junction. Med Oncol. 2015;32:168. https://doi.org/10.1007/s12032-015-0618-7.
Google Scholar
Terai S, Fushida S, Tsukada T, Kinoshita J, Oyama K, Okamoto K. Bone marrow derived “fibrocytes” contribute to tumor proliferation and fibrosis in gastric cancer. Gastric Cancer. 2015;18:306–13. https://doi.org/10.1007/s10120-014-0380-0.
Google Scholar
Ullah A, Wang K, Wu P, Oupicky D, Sun M.
CXCR4-targeted liposomal mediated co-delivery of pirfenidone and AMD3100 for the treatment of TGFβ-induced HSC-T6 cells activation
. Int J Nanomedicine. 2019;Volume 14:2927–44. https://doi.org/10.2147/IJN.S171280.
Google Scholar
Chen Y, Huang Y, Reiberger T, Duyverman AM, Huang P, Samuel R, et al. Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen–positive myeloid cell infiltration in mice. Hepatology. 2014;59:1435–47. https://doi.org/10.1002/hep.26790.
Google Scholar
Thuya WL, Cao Y, Ho PC-L, Wong AL-A, Wang L, Zhou J, et al. Insights into IL-6/JAK/STAT3 signaling in the tumor microenvironment: Implications for cancer therapy. Cytokine Growth Factor Rev. 2025;85:26–42. https://doi.org/10.1016/j.cytogfr.2025.01.003.
Google Scholar
Li Y, Zhao J, Yin Y, Li K, Zhang C, Zheng Y. The role of IL-6 in fibrotic diseases: molecular and cellular mechanisms. Int J Biol Sci. 2022;18:5405–14. https://doi.org/10.7150/ijbs.75876.
Google Scholar
Montero P, Milara J, Roger I, Cortijo J. Role of JAK/STAT in interstitial lung diseases; molecular and cellular mechanisms. Int J Mol Sci. 2021;22:6211. https://doi.org/10.3390/ijms22126211.
Google Scholar
Cortés AA, Diaz RA, Hernández-Campo P, Gorrochategui J, Primo D, Robles A, et al. Ruxolitinib in combination with prednisone and nilotinib exhibit synergistic effects in human cells lines and primary cells from myeloproliferative neoplasms. Haematologica. 2019;104:937–46. https://doi.org/10.3324/haematol.2018.201038.
Google Scholar
Han C, Wang L-J, Dong Z-Q, Wang P-Y, Lv Y-W, Wang D, et al. Nintedanib alleviates chronic pancreatitis by inhibiting the activation of pancreatic stellate cells via the JAK/STAT3 and ERK1/2 pathways. Dig Dis Sci. 2023;68:3644–59. https://doi.org/10.1007/s10620-023-08052-7.
Google Scholar
Avsharian LC, Loganathan S, Ebelt ND, Shalamzari AF, Rodarte Muñoz I, Manuel ER. Tumor-colonizing E. coli expressing both collagenase and hyaluronidase enhances therapeutic efficacy of gemcitabine in pancreatic cancer models. Biomolecules. 2024;14:1458. https://doi.org/10.3390/biom14111458.
Google Scholar
Pickup MW, Mouw JK, Weaver VM. The extracellular matrix modulates the hallmarks of cancer. EMBO Rep. 2014;15:1243–53. https://doi.org/10.15252/embr.201439246.
Google Scholar
Handorf AM, Yaxian Z, Matthew AH, Li W-J. Tissue Stiffness Dictates Development, Homeostasis, and Disease Progression. Organogenesis. 2015;11:1–15. https://doi.org/10.1080/15476278.2015.1019687.
Google Scholar
Engler AJ, Sen S, Sweeney HL, Discher DE. Matrix elasticity directs stem cell lineage specification. Cell. 2006;126:677–89. https://doi.org/10.1016/j.cell.2006.06.044.
Google Scholar
Paszek MJ, Zahir N, Johnson KR, Lakins JN, Rozenberg GI, Gefen A, et al. Tensional homeostasis and the malignant phenotype. Cancer Cell. 2005;8:241–54. https://doi.org/10.1016/j.ccr.2005.08.010.
Google Scholar
Provenzano PP, Inman DR, Eliceiri KW, Keely PJ. Matrix density-induced mechanoregulation of breast cell phenotype, signaling and gene expression through a FAK–ERK linkage. Oncogene. 2009;28:4326–43. https://doi.org/10.1038/onc.2009.299.
Google Scholar
Morris BA, Burkel B, Ponik SM, Fan J, Condeelis JS, Aguirre-Ghiso JA, et al. Collagen matrix density drives the metabolic shift in breast cancer cells. EBioMedicine. 2016;13:146–56. https://doi.org/10.1016/j.ebiom.2016.10.012.
Google Scholar
Gunzer M, Schäfer A, Borgmann S, Grabbe S, Zänker KS, Bröcker E-B, et al. Antigen Presentation in Extracellular Matrix: Interactions of T Cells with Dendritic Cells Are Dynamic, Short Lived, and Sequential. Immunity. 2000;13:323–32. https://doi.org/10.1016/S1074-7613(00)00032-7.
Google Scholar
Dustin ML, de Fougerolles AR. Reprograming T cells: the role of extracellular matrix in coordination of T cell activation and migration. Curr Opin Immunol. 2001;13:286–90. https://doi.org/10.1016/S0952-7915(00)00217-X.
Google Scholar
Dustin ML, Choudhuri K. Signaling and polarized communication across the T cell immunological synapse. Annu Rev Cell Dev Biol. 2016;32:303–25. https://doi.org/10.1146/annurev-cellbio-100814-125330.
Google Scholar
Kuczek DE, Larsen AMH, Thorseth M-L, Carretta M, Kalvisa A, Siersbæk MS, et al. Collagen density regulates the activity of tumor-infiltrating T cells. J Immunother Cancer. 2019;7:68. https://doi.org/10.1186/s40425-019-0556-6.
Google Scholar
Rømer AMA, Thorseth M-L, Madsen DH. Immune modulatory properties of collagen in cancer. Front Immunol. 2021;12:791453. https://doi.org/10.3389/fimmu.2021.791453.
Google Scholar
Nicolas-Boluda A, Vaquero J, Vimeux L, Guilbert T, Barrin S, Kantari-Mimoun C, et al. Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment. Elife. 2021. https://doi.org/10.7554/eLife.58688.
Google Scholar
Zhao Z, Li Q, Qu C, Jiang Z, Jia G, Lan G, et al. A collagenase nanogel backpack improves CAR-T cell therapy outcomes in pancreatic cancer. Nat Nanotechnol. 2025. https://doi.org/10.1038/s41565-025-01924-1.
Google Scholar
Larsen AMH, Kuczek DE, Kalvisa A, Siersbæk MS, Thorseth M-L, Johansen AZ, et al. Collagen density modulates the immunosuppressive functions of macrophages. J Immunol. 2020;205:1461–72. https://doi.org/10.4049/jimmunol.1900789.
Google Scholar
Peng DH, Rodriguez BL, Diao L, Chen L, Wang J, Byers LA, et al. Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion. Nat Commun. 2020;11:4520. https://doi.org/10.1038/s41467-020-18298-8.
Google Scholar
Xu L, Shanlong W, Jufeng L, Jie L, Li B. Cancer immunotherapy based on blocking immune suppression mediated by an immune modulator LAIR-1. Oncoimmunology. 2020;9:1740477. https://doi.org/10.1080/2162402X.2020.1740477.
Google Scholar
Ramos MIP, Tian L, de Ruiter EJ, Song C, Paucarmayta A, Singh A, et al. Cancer immunotherapy by NC410, a LAIR-2 Fc protein blocking human LAIR-collagen interaction. Elife. 2021;10:e62927. https://doi.org/10.7554/eLife.62927.
Google Scholar
Piper M, Mueller AC, Karam SD. The interplay between cancer associated fibroblasts and immune cells in the context of radiation therapy. Mol Carcinog. 2020;59:754–65. https://doi.org/10.1002/mc.23205.
Google Scholar
Oncogenic collagen I homotrimers from cancer cells bind to α3β1 integrin and impact tumor microbiome and immunity to promote pancreatic cancer. Cancer Cell. 2022;40:818–834.e9. https://doi.org/10.1016/j.ccell.2022.06.011
Dwyer AR, Truong TH, Ostrander JH, Lange CA. 90 years of progesterone: steroid receptors as MAPK signaling sensors in breast cancer: let the fates decide. J Mol Endocrinol. 2020. https://doi.org/10.1530/JME-19-0274.
Google Scholar
Lebbink RJ, de Ruiter T, Adelmeijer J, Brenkman AB, van Helvoort JM, Koch M, et al. Collagens are functional, high affinity ligands for the inhibitory immune receptor LAIR-1. J Exp Med. 2006;203:1419–25. https://doi.org/10.1084/jem.20052554.
Google Scholar
A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma https://clinicaltrials.gov/study/NCT02715804?cond=PDAC%20-%20Pancreatic%20Ductal%20Adenocarcinoma&intr=PEGPH20&rank=7. 2025.
Maneval DC, L. Caster C, Derunes C, Locke KW, Muhsin M, Sauter S, et al. Pegvorhyaluronidase alfa. Polymer-Protein Conjugates. Elsevier; 2020; 175–204. https://doi.org/10.1016/B978-0-444-64081-9.00009-7
Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69:562–73. https://doi.org/10.1016/j.cardiores.2005.12.002.
Google Scholar
Bond MD, Van Wart HE. Characterization of the individual collagenases from Clostridium histolyticum. Biochemistry. 1984;23:3085–91. https://doi.org/10.1021/bi00308a036.
Google Scholar
Mandl I, Zipper H, Ferguson LT. Clostridium histolyticum collagenase: its purification and properties. Arch Biochem Biophys. 1958;74:465–75. https://doi.org/10.1016/0003-9861(58)90017-1.
Google Scholar
Fágáin CÓ. Understanding and increasing protein stability. Biochimica et Biophysica Acta (BBA). 1995;1252:1–14. https://doi.org/10.1016/0167-4838(95)00133-F.
Google Scholar
Tran S, DeGiovanni P-J, Piel B, Rai P. Cancer nanomedicine: a review of recent success in drug delivery. Clin Transl Med. 2017;6:44. https://doi.org/10.1186/s40169-017-0175-0.
Google Scholar
Raj S, Khurana S, Choudhari R, Kesari KK, Kamal MA, Garg N, et al. Specific targeting cancer cells with nanoparticles and drug delivery in cancer therapy. Semin Cancer Biol. 2021;69:166–77. https://doi.org/10.1016/j.semcancer.2019.11.002.
Google Scholar
Foley CJ, Luo C, O’Callaghan K, Hinds PW, Covic L, Kuliopulos A. Matrix metalloprotease-1a promotes tumorigenesis and metastasis. J Biol Chem. 2012;287:24330–8. https://doi.org/10.1074/jbc.M112.356303.
Google Scholar
Cao J, Chiarelli C, Kozarekar P, Adler HL. Membrane type 1-matrix metalloproteinase promotes human prostate cancer invasion and metastasis. Thromb Haemost. 2017;93:770–8. https://doi.org/10.1160/TH04-08-0555.
Google Scholar
Kudo Y, Iizuka S, Yoshida M, Tsunematsu T, Kondo T, Subarnbhesaj A, et al. Matrix metalloproteinase-13 (MMP-13) directly and indirectly promotes tumor angiogenesis*. J Biol Chem. 2012;287:38716–28. https://doi.org/10.1074/jbc.M112.373159.
Google Scholar
Radisky ES, Radisky DC. Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J Mammary Gland Biol Neoplasia. 2010;15:201–12. https://doi.org/10.1007/s10911-010-9177-x.
Google Scholar
Eble JA, Niland S. The extracellular matrix in tumor progression and metastasis. Clin Exp Metastasis. 2019;36:171–98. https://doi.org/10.1007/s10585-019-09966-1.
Google Scholar
Bayer SV, Grither WR, Brenot A, Hwang PY, Barcus CE, Ernst M, et al. DDR2 controls breast tumor stiffness and metastasis by regulating integrin mediated mechanotransduction in CAFs. Elife. 2019. https://doi.org/10.7554/eLife.45508.
Google Scholar
Akinjiyan FA, Ibitoye Z, Zhao P, Shriver LP, Patti GJ, Longmore GD, et al. DDR2-regulated arginase activity in ovarian cancer-associated fibroblasts promotes collagen production and tumor progression. Oncogene. 2024;43:189–201. https://doi.org/10.1038/s41388-023-02884-3.
Google Scholar
Jung E, Kim TY, Han J, Lee KY, Shin SY. TLR2–EGR1 signaling axis modulates TGFβ1-induced differentiation of fibroblasts into myofibroblasts in pulmonary fibrosis. Biochem Biophys Res Commun. 2024;736:150836. https://doi.org/10.1016/j.bbrc.2024.150836.
Google Scholar
Diehm YF, Jost Y, Kotsougiani-Fischer D, Haug V, Splinter M, Häring P, et al. The treatment of capsular contracture around breast implants induced by fractionated irradiation: the collagenase of the bacterium Clostridium histolyticum as a novel therapeutic approach. Aesthet Plast Surg. 2021;45:1273–81. https://doi.org/10.1007/s00266-020-01970-1.
Google Scholar
Alkasalias T, Moyano-Galceran L, Arsenian-Henriksson M, Lehti K. Fibroblasts in the tumor microenvironment: shield or spear? Int J Mol Sci. 2018;19:1532. https://doi.org/10.3390/ijms19051532.
Google Scholar
Høye AM, Erler JT. Structural ECM components in the premetastatic and metastatic niche. Am J Physiol Cell Physiol. 2016;310:C955–67. https://doi.org/10.1152/ajpcell.00326.2015.
Google Scholar
Mohan V, Das A, Sagi I. Emerging roles of ECM remodeling processes in cancer. Semin Cancer Biol. 2020;62:192–200. https://doi.org/10.1016/j.semcancer.2019.09.004.
Google Scholar
Okada M, Oba Y, Yamawaki H. Endostatin stimulates proliferation and migration of adult rat cardiac fibroblasts through PI3K/Akt pathway. Eur J Pharmacol. 2015;750:20–6. https://doi.org/10.1016/j.ejphar.2015.01.019.
Google Scholar
Favreau AJ, Vary CPH, Brooks PC, Sathyanarayana P. Cryptic collagen IV promotes cell migration and adhesion in myeloid leukemia. Cancer Med. 2014;3:265–72. https://doi.org/10.1002/cam4.203.
Google Scholar
Mierke CT. Extracellular matrix cues regulate mechanosensing and mechanotransduction of cancer cells. Cells. 2024;13:96. https://doi.org/10.3390/cells13010096.
Google Scholar
Pankova D, Jiang Y, Chatzifrangkeskou M, Vendrell I, Buzzelli J, Ryan A, et al. RASSF 1A controls tissue stiffness and cancer stem-like cells in lung adenocarcinoma. EMBO J. 2019. https://doi.org/10.5252/embj.2018100532.
Google Scholar
Continue Reading